Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference</title><author><name sortKey="Jang, Ji Yon Agnes" sort="Jang, Ji Yon Agnes" uniqKey="Jang J" first="Ji Yon Agnes" last="Jang">Ji Yon Agnes Jang</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Yanaihara, Nozomu" sort="Yanaihara, Nozomu" uniqKey="Yanaihara N" first="Nozomu" last="Yanaihara">Nozomu Yanaihara</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation><nlm:aff id="A2">Unité Cancer de la Femme et Recherche Clinique, Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, Université Paris Descartes, Paris,<country>France</country>.</nlm:aff></affiliation></author><author><name sortKey="Mikami, Yoshiki" sort="Mikami, Yoshiki" uniqKey="Mikami Y" first="Yoshiki" last="Mikami">Yoshiki Mikami</name><affiliation><nlm:aff id="A3">Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Oda, Katsutoshi" sort="Oda, Katsutoshi" uniqKey="Oda K" first="Katsutoshi" last="Oda">Katsutoshi Oda</name><affiliation><nlm:aff id="A4">Department of Obstetrics and Gynecology, Graduate School of Medicine, University of Tokyo, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Bookman, Michael" sort="Bookman, Michael" uniqKey="Bookman M" first="Michael" last="Bookman">Michael Bookman</name><affiliation><nlm:aff id="A5">US Oncology Research and Arizona Oncology, Tucson, AZ,<country>USA</country>.</nlm:aff></affiliation></author><author><name sortKey="Ledermann, Jonathan" sort="Ledermann, Jonathan" uniqKey="Ledermann J" first="Jonathan" last="Ledermann">Jonathan Ledermann</name><affiliation><nlm:aff id="A6">UCL Cancer Institute, University College London, London,<country>UK</country>.</nlm:aff></affiliation></author><author><name sortKey="Shimada, Muneaki" sort="Shimada, Muneaki" uniqKey="Shimada M" first="Muneaki" last="Shimada">Muneaki Shimada</name><affiliation><nlm:aff id="A7">Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kiyokawa, Takako" sort="Kiyokawa, Takako" uniqKey="Kiyokawa T" first="Takako" last="Kiyokawa">Takako Kiyokawa</name><affiliation><nlm:aff id="A8">Department of Pathology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kim, Byoung Gie" sort="Kim, Byoung Gie" uniqKey="Kim B" first="Byoung-Gie" last="Kim">Byoung-Gie Kim</name><affiliation><nlm:aff id="A9">Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,<country>Korea</country>.</nlm:aff></affiliation></author><author><name sortKey="Matsumura, Noriomi" sort="Matsumura, Noriomi" uniqKey="Matsumura N" first="Noriomi" last="Matsumura">Noriomi Matsumura</name><affiliation><nlm:aff id="A10">Department of Obstetrics and Gynecology, Kyoto University, Kyoto,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kaku, Tsunehisa" sort="Kaku, Tsunehisa" uniqKey="Kaku T" first="Tsunehisa" last="Kaku">Tsunehisa Kaku</name><affiliation><nlm:aff id="A11">Department of Health Sciences, Graduate School of Medical Science, Kyushu University, Fukuoka,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kuroda, Takafumi" sort="Kuroda, Takafumi" uniqKey="Kuroda T" first="Takafumi" last="Kuroda">Takafumi Kuroda</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Nagayoshi, Yoko" sort="Nagayoshi, Yoko" uniqKey="Nagayoshi Y" first="Yoko" last="Nagayoshi">Yoko Nagayoshi</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kawabata, Ayako" sort="Kawabata, Ayako" uniqKey="Kawabata A" first="Ayako" last="Kawabata">Ayako Kawabata</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Iida, Yasushi" sort="Iida, Yasushi" uniqKey="Iida Y" first="Yasushi" last="Iida">Yasushi Iida</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kim, Jae Weon" sort="Kim, Jae Weon" uniqKey="Kim J" first="Jae-Weon" last="Kim">Jae-Weon Kim</name><affiliation><nlm:aff id="A12">Department of Obstetrics and Gynecology, Seoul National University, Seoul,<country>Korea</country>.</nlm:aff></affiliation></author><author><name sortKey="Quinn, Michael" sort="Quinn, Michael" uniqKey="Quinn M" first="Michael" last="Quinn">Michael Quinn</name><affiliation><nlm:aff id="A13">Women's Cancer Research Center, Royal Women's Hospital, Melbourne,<country>Australia</country>.</nlm:aff></affiliation></author><author><name sortKey="Okamoto, Aikou" sort="Okamoto, Aikou" uniqKey="Okamoto A" first="Aikou" last="Okamoto">Aikou Okamoto</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28541641</idno><idno type="pmc">5447152</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447152</idno><idno type="RBID">PMC:5447152</idno><idno type="doi">10.3802/jgo.2017.28.e54</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">002F50</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002F50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference</title><author><name sortKey="Jang, Ji Yon Agnes" sort="Jang, Ji Yon Agnes" uniqKey="Jang J" first="Ji Yon Agnes" last="Jang">Ji Yon Agnes Jang</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Yanaihara, Nozomu" sort="Yanaihara, Nozomu" uniqKey="Yanaihara N" first="Nozomu" last="Yanaihara">Nozomu Yanaihara</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation><nlm:aff id="A2">Unité Cancer de la Femme et Recherche Clinique, Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, Université Paris Descartes, Paris,<country>France</country>.</nlm:aff></affiliation></author><author><name sortKey="Mikami, Yoshiki" sort="Mikami, Yoshiki" uniqKey="Mikami Y" first="Yoshiki" last="Mikami">Yoshiki Mikami</name><affiliation><nlm:aff id="A3">Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Oda, Katsutoshi" sort="Oda, Katsutoshi" uniqKey="Oda K" first="Katsutoshi" last="Oda">Katsutoshi Oda</name><affiliation><nlm:aff id="A4">Department of Obstetrics and Gynecology, Graduate School of Medicine, University of Tokyo, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Bookman, Michael" sort="Bookman, Michael" uniqKey="Bookman M" first="Michael" last="Bookman">Michael Bookman</name><affiliation><nlm:aff id="A5">US Oncology Research and Arizona Oncology, Tucson, AZ,<country>USA</country>.</nlm:aff></affiliation></author><author><name sortKey="Ledermann, Jonathan" sort="Ledermann, Jonathan" uniqKey="Ledermann J" first="Jonathan" last="Ledermann">Jonathan Ledermann</name><affiliation><nlm:aff id="A6">UCL Cancer Institute, University College London, London,<country>UK</country>.</nlm:aff></affiliation></author><author><name sortKey="Shimada, Muneaki" sort="Shimada, Muneaki" uniqKey="Shimada M" first="Muneaki" last="Shimada">Muneaki Shimada</name><affiliation><nlm:aff id="A7">Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kiyokawa, Takako" sort="Kiyokawa, Takako" uniqKey="Kiyokawa T" first="Takako" last="Kiyokawa">Takako Kiyokawa</name><affiliation><nlm:aff id="A8">Department of Pathology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kim, Byoung Gie" sort="Kim, Byoung Gie" uniqKey="Kim B" first="Byoung-Gie" last="Kim">Byoung-Gie Kim</name><affiliation><nlm:aff id="A9">Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,<country>Korea</country>.</nlm:aff></affiliation></author><author><name sortKey="Matsumura, Noriomi" sort="Matsumura, Noriomi" uniqKey="Matsumura N" first="Noriomi" last="Matsumura">Noriomi Matsumura</name><affiliation><nlm:aff id="A10">Department of Obstetrics and Gynecology, Kyoto University, Kyoto,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kaku, Tsunehisa" sort="Kaku, Tsunehisa" uniqKey="Kaku T" first="Tsunehisa" last="Kaku">Tsunehisa Kaku</name><affiliation><nlm:aff id="A11">Department of Health Sciences, Graduate School of Medical Science, Kyushu University, Fukuoka,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kuroda, Takafumi" sort="Kuroda, Takafumi" uniqKey="Kuroda T" first="Takafumi" last="Kuroda">Takafumi Kuroda</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Nagayoshi, Yoko" sort="Nagayoshi, Yoko" uniqKey="Nagayoshi Y" first="Yoko" last="Nagayoshi">Yoko Nagayoshi</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kawabata, Ayako" sort="Kawabata, Ayako" uniqKey="Kawabata A" first="Ayako" last="Kawabata">Ayako Kawabata</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Iida, Yasushi" sort="Iida, Yasushi" uniqKey="Iida Y" first="Yasushi" last="Iida">Yasushi Iida</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author><author><name sortKey="Kim, Jae Weon" sort="Kim, Jae Weon" uniqKey="Kim J" first="Jae-Weon" last="Kim">Jae-Weon Kim</name><affiliation><nlm:aff id="A12">Department of Obstetrics and Gynecology, Seoul National University, Seoul,<country>Korea</country>.</nlm:aff></affiliation></author><author><name sortKey="Quinn, Michael" sort="Quinn, Michael" uniqKey="Quinn M" first="Michael" last="Quinn">Michael Quinn</name><affiliation><nlm:aff id="A13">Women's Cancer Research Center, Royal Women's Hospital, Melbourne,<country>Australia</country>.</nlm:aff></affiliation></author><author><name sortKey="Okamoto, Aikou" sort="Okamoto, Aikou" uniqKey="Okamoto A" first="Aikou" last="Okamoto">Aikou Okamoto</name><affiliation><nlm:aff id="A1">Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Gynecologic Oncology</title><idno type="ISSN">2005-0380</idno><idno type="eISSN">2005-0399</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author><author><name sortKey="Deavers, Mt" uniqKey="Deavers M">MT Deavers</name></author><author><name sortKey="Lu, K" uniqKey="Lu K">K Lu</name></author><author><name sortKey="Bodurka, Dc" uniqKey="Bodurka D">DC Bodurka</name></author><author><name sortKey="Atkinson, En" uniqKey="Atkinson E">EN Atkinson</name></author><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boyd, C" uniqKey="Boyd C">C Boyd</name></author><author><name sortKey="Mccluggage, Wg" uniqKey="Mccluggage W">WG McCluggage</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author><author><name sortKey="Sun, Cc" uniqKey="Sun C">CC Sun</name></author><author><name sortKey="Bodurka, D" uniqKey="Bodurka D">D Bodurka</name></author><author><name sortKey="Coleman, Rl" uniqKey="Coleman R">RL Coleman</name></author><author><name sortKey="Lu, Kh" uniqKey="Lu K">KH Lu</name></author><author><name sortKey="Sood, Ak" uniqKey="Sood A">AK Sood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author><author><name sortKey="Sun, Cc" uniqKey="Sun C">CC Sun</name></author><author><name sortKey="Lu, Kh" uniqKey="Lu K">KH Lu</name></author><author><name sortKey="Coleman, Rl" uniqKey="Coleman R">RL Coleman</name></author><author><name sortKey="Sood, Ak" uniqKey="Sood A">AK Sood</name></author><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schmeler, Km" uniqKey="Schmeler K">KM Schmeler</name></author><author><name sortKey="Sun, Cc" uniqKey="Sun C">CC Sun</name></author><author><name sortKey="Bodurka, Dc" uniqKey="Bodurka D">DC Bodurka</name></author><author><name sortKey="Deavers, Mt" uniqKey="Deavers M">MT Deavers</name></author><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author><author><name sortKey="Coleman, Rl" uniqKey="Coleman R">RL Coleman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Plaxe, Sc" uniqKey="Plaxe S">SC Plaxe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kindelberger, Dw" uniqKey="Kindelberger D">DW Kindelberger</name></author><author><name sortKey="Lee, Y" uniqKey="Lee Y">Y Lee</name></author><author><name sortKey="Miron, A" uniqKey="Miron A">A Miron</name></author><author><name sortKey="Hirsch, Ms" uniqKey="Hirsch M">MS Hirsch</name></author><author><name sortKey="Feltmate, C" uniqKey="Feltmate C">C Feltmate</name></author><author><name sortKey="Medeiros, F" uniqKey="Medeiros F">F Medeiros</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vang, R" uniqKey="Vang R">R Vang</name></author><author><name sortKey="Shih, Im" uniqKey="Shih I">IM Shih</name></author><author><name sortKey="Kurman, Rj" uniqKey="Kurman R">RJ Kurman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonome, T" uniqKey="Bonome T">T Bonome</name></author><author><name sortKey="Lee, Jy" uniqKey="Lee J">JY Lee</name></author><author><name sortKey="Park, Dc" uniqKey="Park D">DC Park</name></author><author><name sortKey="Radonovich, M" uniqKey="Radonovich M">M Radonovich</name></author><author><name sortKey="Pise Masison, C" uniqKey="Pise Masison C">C Pise-Masison</name></author><author><name sortKey="Brady, J" uniqKey="Brady J">J Brady</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kurman, Rj" uniqKey="Kurman R">RJ Kurman</name></author><author><name sortKey="Shih, Im" uniqKey="Shih I">IM Shih</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shih, Im" uniqKey="Shih I">IM Shih</name></author><author><name sortKey="Kurman, Rj" uniqKey="Kurman R">RJ Kurman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuo, Kt" uniqKey="Kuo K">KT Kuo</name></author><author><name sortKey="Guan, B" uniqKey="Guan B">B Guan</name></author><author><name sortKey="Feng, Y" uniqKey="Feng Y">Y Feng</name></author><author><name sortKey="Mao, Tl" uniqKey="Mao T">TL Mao</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X Chen</name></author><author><name sortKey="Jinawath, N" uniqKey="Jinawath N">N Jinawath</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Della Pepa, C" uniqKey="Della Pepa C">C Della Pepa</name></author><author><name sortKey="Tonini, G" uniqKey="Tonini G">G Tonini</name></author><author><name sortKey="Santini, D" uniqKey="Santini D">D Santini</name></author><author><name sortKey="Losito, S" uniqKey="Losito S">S Losito</name></author><author><name sortKey="Pisano, C" uniqKey="Pisano C">C Pisano</name></author><author><name sortKey="Di Napoli, M" uniqKey="Di Napoli M">M Di Napoli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author><author><name sortKey="Bodurka, Dc" uniqKey="Bodurka D">DC Bodurka</name></author><author><name sortKey="Lu, Kh" uniqKey="Lu K">KH Lu</name></author><author><name sortKey="Nathan, Lc" uniqKey="Nathan L">LC Nathan</name></author><author><name sortKey="Milojevic, L" uniqKey="Milojevic L">L Milojevic</name></author><author><name sortKey="Wong, Kk" uniqKey="Wong K">KK Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pearce, Cl" uniqKey="Pearce C">CL Pearce</name></author><author><name sortKey="Templeman, C" uniqKey="Templeman C">C Templeman</name></author><author><name sortKey="Rossing, Ma" uniqKey="Rossing M">MA Rossing</name></author><author><name sortKey="Lee, A" uniqKey="Lee A">A Lee</name></author><author><name sortKey="Near, Am" uniqKey="Near A">AM Near</name></author><author><name sortKey="Webb, Pm" uniqKey="Webb P">PM Webb</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bookman, Ma" uniqKey="Bookman M">MA Bookman</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Mcguire, Wp" uniqKey="Mcguire W">WP McGuire</name></author><author><name sortKey="Harper, Pg" uniqKey="Harper P">PG Harper</name></author><author><name sortKey="Alberts, Ds" uniqKey="Alberts D">DS Alberts</name></author><author><name sortKey="Friedlander, M" uniqKey="Friedlander M">M Friedlander</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du Bois, A" uniqKey="Du Bois A">A du Bois</name></author><author><name sortKey="Weber, B" uniqKey="Weber B">B Weber</name></author><author><name sortKey="Rochon, J" uniqKey="Rochon J">J Rochon</name></author><author><name sortKey="Meier, W" uniqKey="Meier W">W Meier</name></author><author><name sortKey="Goupil, A" uniqKey="Goupil A">A Goupil</name></author><author><name sortKey="Olbricht, S" uniqKey="Olbricht S">S Olbricht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoskins, P" uniqKey="Hoskins P">P Hoskins</name></author><author><name sortKey="Vergote, I" uniqKey="Vergote I">I Vergote</name></author><author><name sortKey="Cervantes, A" uniqKey="Cervantes A">A Cervantes</name></author><author><name sortKey="Tu, D" uniqKey="Tu D">D Tu</name></author><author><name sortKey="Stuart, G" uniqKey="Stuart G">G Stuart</name></author><author><name sortKey="Zola, P" uniqKey="Zola P">P Zola</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pfisterer, J" uniqKey="Pfisterer J">J Pfisterer</name></author><author><name sortKey="Weber, B" uniqKey="Weber B">B Weber</name></author><author><name sortKey="Reuss, A" uniqKey="Reuss A">A Reuss</name></author><author><name sortKey="Kimmig, R" uniqKey="Kimmig R">R Kimmig</name></author><author><name sortKey="Du Bois, A" uniqKey="Du Bois A">A du Bois</name></author><author><name sortKey="Wagner, U" uniqKey="Wagner U">U Wagner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grisham, Rn" uniqKey="Grisham R">RN Grisham</name></author><author><name sortKey="Iyer, G" uniqKey="Iyer G">G Iyer</name></author><author><name sortKey="Sala, E" uniqKey="Sala E">E Sala</name></author><author><name sortKey="Zhou, Q" uniqKey="Zhou Q">Q Zhou</name></author><author><name sortKey="Iasonos, A" uniqKey="Iasonos A">A Iasonos</name></author><author><name sortKey="Delair, D" uniqKey="Delair D">D DeLair</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schmeler, Km" uniqKey="Schmeler K">KM Schmeler</name></author><author><name sortKey="Tao, X" uniqKey="Tao X">X Tao</name></author><author><name sortKey="Sun, Cc" uniqKey="Sun C">CC Sun</name></author><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author><author><name sortKey="Deavers, M" uniqKey="Deavers M">M Deavers</name></author><author><name sortKey="Sood, A" uniqKey="Sood A">A Sood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, Ra" uniqKey="Burger R">RA Burger</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Bookman, Ma" uniqKey="Bookman M">MA Bookman</name></author><author><name sortKey="Fleming, Gf" uniqKey="Fleming G">GF Fleming</name></author><author><name sortKey="Monk, Bj" uniqKey="Monk B">BJ Monk</name></author><author><name sortKey="Huang, H" uniqKey="Huang H">H Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perren, Tj" uniqKey="Perren T">TJ Perren</name></author><author><name sortKey="Swart, Am" uniqKey="Swart A">AM Swart</name></author><author><name sortKey="Pfisterer, J" uniqKey="Pfisterer J">J Pfisterer</name></author><author><name sortKey="Ledermann, Ja" uniqKey="Ledermann J">JA Ledermann</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author><author><name sortKey="Kristensen, G" uniqKey="Kristensen G">G Kristensen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, Kk" uniqKey="Wong K">KK Wong</name></author><author><name sortKey="Lu, Kh" uniqKey="Lu K">KH Lu</name></author><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author><author><name sortKey="Bodurka, Dc" uniqKey="Bodurka D">DC Bodurka</name></author><author><name sortKey="Shvartsman, Hs" uniqKey="Shvartsman H">HS Shvartsman</name></author><author><name sortKey="Schmandt, Re" uniqKey="Schmandt R">RE Schmandt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shirey, Dr" uniqKey="Shirey D">DR Shirey</name></author><author><name sortKey="Kavanagh, Jj" uniqKey="Kavanagh J">JJ Kavanagh</name></author><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author><author><name sortKey="Freedman, Rs" uniqKey="Freedman R">RS Freedman</name></author><author><name sortKey="Copeland, Lj" uniqKey="Copeland L">LJ Copeland</name></author><author><name sortKey="Jones, La" uniqKey="Jones L">LA Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramirez, Pt" uniqKey="Ramirez P">PT Ramirez</name></author><author><name sortKey="Schmeler, Km" uniqKey="Schmeler K">KM Schmeler</name></author><author><name sortKey="Milam, Mr" uniqKey="Milam M">MR Milam</name></author><author><name sortKey="Slomovitz, Bm" uniqKey="Slomovitz B">BM Slomovitz</name></author><author><name sortKey="Smith, Ja" uniqKey="Smith J">JA Smith</name></author><author><name sortKey="Kavanagh, Jj" uniqKey="Kavanagh J">JJ Kavanagh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author><author><name sortKey="Sun, Cc" uniqKey="Sun C">CC Sun</name></author><author><name sortKey="Iyer, Rb" uniqKey="Iyer R">RB Iyer</name></author><author><name sortKey="Malpica, Al" uniqKey="Malpica A">AL Malpica</name></author><author><name sortKey="Kavanagh, Jj" uniqKey="Kavanagh J">JJ Kavanagh</name></author><author><name sortKey="Bodurka, Dc" uniqKey="Bodurka D">DC Bodurka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grisham, Rn" uniqKey="Grisham R">RN Grisham</name></author><author><name sortKey="Iyer, G" uniqKey="Iyer G">G Iyer</name></author><author><name sortKey="Garg, K" uniqKey="Garg K">K Garg</name></author><author><name sortKey="Delair, D" uniqKey="Delair D">D DeLair</name></author><author><name sortKey="Hyman, Dm" uniqKey="Hyman D">DM Hyman</name></author><author><name sortKey="Zhou, Q" uniqKey="Zhou Q">Q Zhou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Combe, P" uniqKey="Combe P">P Combe</name></author><author><name sortKey="Chauvenet, L" uniqKey="Chauvenet L">L Chauvenet</name></author><author><name sortKey="Lefrere Belda, Ma" uniqKey="Lefrere Belda M">MA Lefrère-Belda</name></author><author><name sortKey="Blons, H" uniqKey="Blons H">H Blons</name></author><author><name sortKey="Rousseau, C" uniqKey="Rousseau C">C Rousseau</name></author><author><name sortKey="Oudard, S" uniqKey="Oudard S">S Oudard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Farley, J" uniqKey="Farley J">J Farley</name></author><author><name sortKey="Brady, We" uniqKey="Brady W">WE Brady</name></author><author><name sortKey="Vathipadiekal, V" uniqKey="Vathipadiekal V">V Vathipadiekal</name></author><author><name sortKey="Lankes, Ha" uniqKey="Lankes H">HA Lankes</name></author><author><name sortKey="Coleman, R" uniqKey="Coleman R">R Coleman</name></author><author><name sortKey="Morgan, Ma" uniqKey="Morgan M">MA Morgan</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="King, Er" uniqKey="King E">ER King</name></author><author><name sortKey="Zu, Z" uniqKey="Zu Z">Z Zu</name></author><author><name sortKey="Tsang, Yt" uniqKey="Tsang Y">YT Tsang</name></author><author><name sortKey="Deavers, Mt" uniqKey="Deavers M">MT Deavers</name></author><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author><author><name sortKey="Mok, Sc" uniqKey="Mok S">SC Mok</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seidman, Jd" uniqKey="Seidman J">JD Seidman</name></author><author><name sortKey="Kurman, Rj" uniqKey="Kurman R">RJ Kurman</name></author><author><name sortKey="Ronnett, Bm" uniqKey="Ronnett B">BM Ronnett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shimada, M" uniqKey="Shimada M">M Shimada</name></author><author><name sortKey="Kigawa, J" uniqKey="Kigawa J">J Kigawa</name></author><author><name sortKey="Ohishi, Y" uniqKey="Ohishi Y">Y Ohishi</name></author><author><name sortKey="Yasuda, M" uniqKey="Yasuda M">M Yasuda</name></author><author><name sortKey="Suzuki, M" uniqKey="Suzuki M">M Suzuki</name></author><author><name sortKey="Hiura, M" uniqKey="Hiura M">M Hiura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Kr" uniqKey="Lee K">KR Lee</name></author><author><name sortKey="Scully, Re" uniqKey="Scully R">RE Scully</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rodriguez, Im" uniqKey="Rodriguez I">IM Rodríguez</name></author><author><name sortKey="Prat, J" uniqKey="Prat J">J Prat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riopel, Ma" uniqKey="Riopel M">MA Riopel</name></author><author><name sortKey="Ronnett, Bm" uniqKey="Ronnett B">BM Ronnett</name></author><author><name sortKey="Kurman, Rj" uniqKey="Kurman R">RJ Kurman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khunamornpong, S" uniqKey="Khunamornpong S">S Khunamornpong</name></author><author><name sortKey="Suprasert, P" uniqKey="Suprasert P">P Suprasert</name></author><author><name sortKey="Pojchamarnwiputh, S" uniqKey="Pojchamarnwiputh S">S Pojchamarnwiputh</name></author><author><name sortKey="Na Chiangmai, W" uniqKey="Na Chiangmai W">W Na Chiangmai</name></author><author><name sortKey="Settakorn, J" uniqKey="Settakorn J">J Settakorn</name></author><author><name sortKey="Siriaunkgul, S" uniqKey="Siriaunkgul S">S Siriaunkgul</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Kr" uniqKey="Lee K">KR Lee</name></author><author><name sortKey="Young, Rh" uniqKey="Young R">RH Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Frumovitz, M" uniqKey="Frumovitz M">M Frumovitz</name></author><author><name sortKey="Schmeler, Km" uniqKey="Schmeler K">KM Schmeler</name></author><author><name sortKey="Malpica, A" uniqKey="Malpica A">A Malpica</name></author><author><name sortKey="Sood, Ak" uniqKey="Sood A">AK Sood</name></author><author><name sortKey="Gershenson, Dm" uniqKey="Gershenson D">DM Gershenson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jung, Es" uniqKey="Jung E">ES Jung</name></author><author><name sortKey="Bae, Jh" uniqKey="Bae J">JH Bae</name></author><author><name sortKey="Lee, A" uniqKey="Lee A">A Lee</name></author><author><name sortKey="Choi, Yj" uniqKey="Choi Y">YJ Choi</name></author><author><name sortKey="Park, Js" uniqKey="Park J">JS Park</name></author><author><name sortKey="Lee, Ky" uniqKey="Lee K">KY Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maeda Taniguchi, M" uniqKey="Maeda Taniguchi M">M Maeda-Taniguchi</name></author><author><name sortKey="Ueda, Y" uniqKey="Ueda Y">Y Ueda</name></author><author><name sortKey="Miyake, T" uniqKey="Miyake T">T Miyake</name></author><author><name sortKey="Miyatake, T" uniqKey="Miyatake T">T Miyatake</name></author><author><name sortKey="Kimura, T" uniqKey="Kimura T">T Kimura</name></author><author><name sortKey="Yoshino, K" uniqKey="Yoshino K">K Yoshino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cao, D" uniqKey="Cao D">D Cao</name></author><author><name sortKey="Ji, H" uniqKey="Ji H">H Ji</name></author><author><name sortKey="Ronnett, Bm" uniqKey="Ronnett B">BM Ronnett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pinto, Pb" uniqKey="Pinto P">PB Pinto</name></author><author><name sortKey="Derchain, Sf" uniqKey="Derchain S">SF Derchain</name></author><author><name sortKey="Andrade, La" uniqKey="Andrade L">LA Andrade</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaino, Rj" uniqKey="Zaino R">RJ Zaino</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Lele, Sm" uniqKey="Lele S">SM Lele</name></author><author><name sortKey="Michael, H" uniqKey="Michael H">H Michael</name></author><author><name sortKey="Greer, B" uniqKey="Greer B">B Greer</name></author><author><name sortKey="Bookman, Ma" uniqKey="Bookman M">MA Bookman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winter, We" uniqKey="Winter W">WE Winter</name></author><author><name sortKey="Maxwell, Gl" uniqKey="Maxwell G">GL Maxwell</name></author><author><name sortKey="Tian, C" uniqKey="Tian C">C Tian</name></author><author><name sortKey="Carlson, Jw" uniqKey="Carlson J">JW Carlson</name></author><author><name sortKey="Ozols, Rf" uniqKey="Ozols R">RF Ozols</name></author><author><name sortKey="Rose, Pg" uniqKey="Rose P">PG Rose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alexandre, J" uniqKey="Alexandre J">J Alexandre</name></author><author><name sortKey="Ray Coquard, I" uniqKey="Ray Coquard I">I Ray-Coquard</name></author><author><name sortKey="Selle, F" uniqKey="Selle F">F Selle</name></author><author><name sortKey="Floquet, A" uniqKey="Floquet A">A Floquet</name></author><author><name sortKey="Cottu, P" uniqKey="Cottu P">P Cottu</name></author><author><name sortKey="Weber, B" uniqKey="Weber B">B Weber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tian, C" uniqKey="Tian C">C Tian</name></author><author><name sortKey="Markman, M" uniqKey="Markman M">M Markman</name></author><author><name sortKey="Zaino, R" uniqKey="Zaino R">R Zaino</name></author><author><name sortKey="Ozols, Rf" uniqKey="Ozols R">RF Ozols</name></author><author><name sortKey="Mcguire, Wp" uniqKey="Mcguire W">WP McGuire</name></author><author><name sortKey="Muggia, Fm" uniqKey="Muggia F">FM Muggia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mackay, Hj" uniqKey="Mackay H">HJ Mackay</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Oza, Am" uniqKey="Oza A">AM Oza</name></author><author><name sortKey="Reuss, A" uniqKey="Reuss A">A Reuss</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E Pujade-Lauraine</name></author><author><name sortKey="Swart, Am" uniqKey="Swart A">AM Swart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gore, Me" uniqKey="Gore M">ME Gore</name></author><author><name sortKey="Hackshaw, A" uniqKey="Hackshaw A">A Hackshaw</name></author><author><name sortKey="Brady, We" uniqKey="Brady W">WE Brady</name></author><author><name sortKey="Penson, Rt" uniqKey="Penson R">RT Penson</name></author><author><name sortKey="Zaino, Rj" uniqKey="Zaino R">RJ Zaino</name></author><author><name sortKey="Mccluggage, Wg" uniqKey="Mccluggage W">WG McCluggage</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anglesio, Ms" uniqKey="Anglesio M">MS Anglesio</name></author><author><name sortKey="Kommoss, S" uniqKey="Kommoss S">S Kommoss</name></author><author><name sortKey="Tolcher, Mc" uniqKey="Tolcher M">MC Tolcher</name></author><author><name sortKey="Clarke, B" uniqKey="Clarke B">B Clarke</name></author><author><name sortKey="Galletta, L" uniqKey="Galletta L">L Galletta</name></author><author><name sortKey="Porter, H" uniqKey="Porter H">H Porter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chay, Wy" uniqKey="Chay W">WY Chay</name></author><author><name sortKey="Chew, Sh" uniqKey="Chew S">SH Chew</name></author><author><name sortKey="Ong, Ws" uniqKey="Ong W">WS Ong</name></author><author><name sortKey="Busmanis, I" uniqKey="Busmanis I">I Busmanis</name></author><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Thung, S" uniqKey="Thung S">S Thung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcalpine, Jn" uniqKey="Mcalpine J">JN McAlpine</name></author><author><name sortKey="Wiegand, Kc" uniqKey="Wiegand K">KC Wiegand</name></author><author><name sortKey="Vang, R" uniqKey="Vang R">R Vang</name></author><author><name sortKey="Ronnett, Bm" uniqKey="Ronnett B">BM Ronnett</name></author><author><name sortKey="Adamiak, A" uniqKey="Adamiak A">A Adamiak</name></author><author><name sortKey="Kobel, M" uniqKey="Kobel M">M Köbel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, Wl" uniqKey="Lin W">WL Lin</name></author><author><name sortKey="Kuo, Wh" uniqKey="Kuo W">WH Kuo</name></author><author><name sortKey="Chen, Fl" uniqKey="Chen F">FL Chen</name></author><author><name sortKey="Lee, My" uniqKey="Lee M">MY Lee</name></author><author><name sortKey="Ruan, A" uniqKey="Ruan A">A Ruan</name></author><author><name sortKey="Tyan, Ys" uniqKey="Tyan Y">YS Tyan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anglesio, Ms" uniqKey="Anglesio M">MS Anglesio</name></author><author><name sortKey="Carey, Ms" uniqKey="Carey M">MS Carey</name></author><author><name sortKey="Kobel, M" uniqKey="Kobel M">M Köbel</name></author><author><name sortKey="Mackay, H" uniqKey="Mackay H">H Mackay</name></author><author><name sortKey="Huntsman, Dg" uniqKey="Huntsman D">DG Huntsman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Del Carmen, Mg" uniqKey="Del Carmen M">MG del Carmen</name></author><author><name sortKey="Birrer, M" uniqKey="Birrer M">M Birrer</name></author><author><name sortKey="Schorge, Jo" uniqKey="Schorge J">JO Schorge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogawa, S" uniqKey="Ogawa S">S Ogawa</name></author><author><name sortKey="Kaku, T" uniqKey="Kaku T">T Kaku</name></author><author><name sortKey="Amada, S" uniqKey="Amada S">S Amada</name></author><author><name sortKey="Kobayashi, H" uniqKey="Kobayashi H">H Kobayashi</name></author><author><name sortKey="Hirakawa, T" uniqKey="Hirakawa T">T Hirakawa</name></author><author><name sortKey="Ariyoshi, K" uniqKey="Ariyoshi K">K Ariyoshi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kigawa, J" uniqKey="Kigawa J">J Kigawa</name></author><author><name sortKey="Kaku, T" uniqKey="Kaku T">T Kaku</name></author><author><name sortKey="Sugiyama, T" uniqKey="Sugiyama T">T Sugiyama</name></author><author><name sortKey="Silverberg, Sg" uniqKey="Silverberg S">SG Silverberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sugiyama, T" uniqKey="Sugiyama T">T Sugiyama</name></author><author><name sortKey="Kamura, T" uniqKey="Kamura T">T Kamura</name></author><author><name sortKey="Kigawa, J" uniqKey="Kigawa J">J Kigawa</name></author><author><name sortKey="Terakawa, N" uniqKey="Terakawa N">N Terakawa</name></author><author><name sortKey="Kikuchi, Y" uniqKey="Kikuchi Y">Y Kikuchi</name></author><author><name sortKey="Kita, T" uniqKey="Kita T">T Kita</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gounaris, I" uniqKey="Gounaris I">I Gounaris</name></author><author><name sortKey="Brenton, Jd" uniqKey="Brenton J">JD Brenton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamamoto, S" uniqKey="Yamamoto S">S Yamamoto</name></author><author><name sortKey="Tsuda, H" uniqKey="Tsuda H">H Tsuda</name></author><author><name sortKey="Takano, M" uniqKey="Takano M">M Takano</name></author><author><name sortKey="Iwaya, K" uniqKey="Iwaya K">K Iwaya</name></author><author><name sortKey="Tamai, S" uniqKey="Tamai S">S Tamai</name></author><author><name sortKey="Matsubara, O" uniqKey="Matsubara O">O Matsubara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilson, Bg" uniqKey="Wilson B">BG Wilson</name></author><author><name sortKey="Roberts, Cw" uniqKey="Roberts C">CW Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shigetomi, H" uniqKey="Shigetomi H">H Shigetomi</name></author><author><name sortKey="Tsunemi, T" uniqKey="Tsunemi T">T Tsunemi</name></author><author><name sortKey="Haruta, S" uniqKey="Haruta S">S Haruta</name></author><author><name sortKey="Kajihara, H" uniqKey="Kajihara H">H Kajihara</name></author><author><name sortKey="Yoshizawa, Y" uniqKey="Yoshizawa Y">Y Yoshizawa</name></author><author><name sortKey="Tanase, Y" uniqKey="Tanase Y">Y Tanase</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jones, S" uniqKey="Jones S">S Jones</name></author><author><name sortKey="Wang, Tl" uniqKey="Wang T">TL Wang</name></author><author><name sortKey="Shih, Im" uniqKey="Shih I">IM Shih</name></author><author><name sortKey="Mao, Tl" uniqKey="Mao T">TL Mao</name></author><author><name sortKey="Nakayama, K" uniqKey="Nakayama K">K Nakayama</name></author><author><name sortKey="Roden, R" uniqKey="Roden R">R Roden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Samartzis, Ep" uniqKey="Samartzis E">EP Samartzis</name></author><author><name sortKey="Noske, A" uniqKey="Noske A">A Noske</name></author><author><name sortKey="Dedes, Kj" uniqKey="Dedes K">KJ Dedes</name></author><author><name sortKey="Fink, D" uniqKey="Fink D">D Fink</name></author><author><name sortKey="Imesch, P" uniqKey="Imesch P">P Imesch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Okamoto, T" uniqKey="Okamoto T">T Okamoto</name></author><author><name sortKey="Mandai, M" uniqKey="Mandai M">M Mandai</name></author><author><name sortKey="Matsumura, N" uniqKey="Matsumura N">N Matsumura</name></author><author><name sortKey="Yamaguchi, K" uniqKey="Yamaguchi K">K Yamaguchi</name></author><author><name sortKey="Kondoh, H" uniqKey="Kondoh H">H Kondoh</name></author><author><name sortKey="Amano, Y" uniqKey="Amano Y">Y Amano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mandai, M" uniqKey="Mandai M">M Mandai</name></author><author><name sortKey="Amano, Y" uniqKey="Amano Y">Y Amano</name></author><author><name sortKey="Yamaguchi, K" uniqKey="Yamaguchi K">K Yamaguchi</name></author><author><name sortKey="Matsumura, N" uniqKey="Matsumura N">N Matsumura</name></author><author><name sortKey="Baba, T" uniqKey="Baba T">T Baba</name></author><author><name sortKey="Konishi, I" uniqKey="Konishi I">I Konishi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xia, P" uniqKey="Xia P">P Xia</name></author><author><name sortKey="Xu, Xy" uniqKey="Xu X">XY Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, H" uniqKey="Li H">H Li</name></author><author><name sortKey="Zeng, J" uniqKey="Zeng J">J Zeng</name></author><author><name sortKey="Shen, K" uniqKey="Shen K">K Shen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mabuchi, S" uniqKey="Mabuchi S">S Mabuchi</name></author><author><name sortKey="Kuroda, H" uniqKey="Kuroda H">H Kuroda</name></author><author><name sortKey="Takahashi, R" uniqKey="Takahashi R">R Takahashi</name></author><author><name sortKey="Sasano, T" uniqKey="Sasano T">T Sasano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rahman, M" uniqKey="Rahman M">M Rahman</name></author><author><name sortKey="Nakayama, K" uniqKey="Nakayama K">K Nakayama</name></author><author><name sortKey="Rahman, Mt" uniqKey="Rahman M">MT Rahman</name></author><author><name sortKey="Nakayama, N" uniqKey="Nakayama N">N Nakayama</name></author><author><name sortKey="Ishikawa, M" uniqKey="Ishikawa M">M Ishikawa</name></author><author><name sortKey="Katagiri, A" uniqKey="Katagiri A">A Katagiri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, C" uniqKey="Wong C">C Wong</name></author><author><name sortKey="Wellman, Tl" uniqKey="Wellman T">TL Wellman</name></author><author><name sortKey="Lounsbury, Km" uniqKey="Lounsbury K">KM Lounsbury</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Siddiqui, Gk" uniqKey="Siddiqui G">GK Siddiqui</name></author><author><name sortKey="Maclean, Ab" uniqKey="Maclean A">AB Maclean</name></author><author><name sortKey="Elmasry, K" uniqKey="Elmasry K">K Elmasry</name></author><author><name sortKey="Wong Te Fong, A" uniqKey="Wong Te Fong A">A Wong te Fong</name></author><author><name sortKey="Morris, Rw" uniqKey="Morris R">RW Morris</name></author><author><name sortKey="Rashid, M" uniqKey="Rashid M">M Rashid</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mabuchi, S" uniqKey="Mabuchi S">S Mabuchi</name></author><author><name sortKey="Kawase, C" uniqKey="Kawase C">C Kawase</name></author><author><name sortKey="Altomare, Da" uniqKey="Altomare D">DA Altomare</name></author><author><name sortKey="Morishige, K" uniqKey="Morishige K">K Morishige</name></author><author><name sortKey="Hayashi, M" uniqKey="Hayashi M">M Hayashi</name></author><author><name sortKey="Sawada, K" uniqKey="Sawada K">K Sawada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoskins, Wj" uniqKey="Hoskins W">WJ Hoskins</name></author><author><name sortKey="Mcguire, Wp" uniqKey="Mcguire W">WP McGuire</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Homesley, Hd" uniqKey="Homesley H">HD Homesley</name></author><author><name sortKey="Creasman, Wt" uniqKey="Creasman W">WT Creasman</name></author><author><name sortKey="Berman, M" uniqKey="Berman M">M Berman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takano, M" uniqKey="Takano M">M Takano</name></author><author><name sortKey="Tsuda, H" uniqKey="Tsuda H">H Tsuda</name></author><author><name sortKey="Sugiyama, T" uniqKey="Sugiyama T">T Sugiyama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sakuragi, N" uniqKey="Sakuragi N">N Sakuragi</name></author><author><name sortKey="Yamada, H" uniqKey="Yamada H">H Yamada</name></author><author><name sortKey="Oikawa, M" uniqKey="Oikawa M">M Oikawa</name></author><author><name sortKey="Okuyama, K" uniqKey="Okuyama K">K Okuyama</name></author><author><name sortKey="Fujino, T" uniqKey="Fujino T">T Fujino</name></author><author><name sortKey="Sagawa, T" uniqKey="Sagawa T">T Sagawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Negishi, H" uniqKey="Negishi H">H Negishi</name></author><author><name sortKey="Takeda, M" uniqKey="Takeda M">M Takeda</name></author><author><name sortKey="Fujimoto, T" uniqKey="Fujimoto T">T Fujimoto</name></author><author><name sortKey="Todo, Y" uniqKey="Todo Y">Y Todo</name></author><author><name sortKey="Ebina, Y" uniqKey="Ebina Y">Y Ebina</name></author><author><name sortKey="Watari, H" uniqKey="Watari H">H Watari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Magazzino, F" uniqKey="Magazzino F">F Magazzino</name></author><author><name sortKey="Katsaros, D" uniqKey="Katsaros D">D Katsaros</name></author><author><name sortKey="Ottaiano, A" uniqKey="Ottaiano A">A Ottaiano</name></author><author><name sortKey="Gadducci, A" uniqKey="Gadducci A">A Gadducci</name></author><author><name sortKey="Pisano, C" uniqKey="Pisano C">C Pisano</name></author><author><name sortKey="Sorio, R" uniqKey="Sorio R">R Sorio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jk" uniqKey="Chan J">JK Chan</name></author><author><name sortKey="Munro, Eg" uniqKey="Munro E">EG Munro</name></author><author><name sortKey="Cheung, Mk" uniqKey="Cheung M">MK Cheung</name></author><author><name sortKey="Husain, A" uniqKey="Husain A">A Husain</name></author><author><name sortKey="Teng, Nn" uniqKey="Teng N">NN Teng</name></author><author><name sortKey="Berek, Js" uniqKey="Berek J">JS Berek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suzuki, S" uniqKey="Suzuki S">S Suzuki</name></author><author><name sortKey="Kajiyama, H" uniqKey="Kajiyama H">H Kajiyama</name></author><author><name sortKey="Shibata, K" uniqKey="Shibata K">K Shibata</name></author><author><name sortKey="Ino, K" uniqKey="Ino K">K Ino</name></author><author><name sortKey="Nawa, A" uniqKey="Nawa A">A Nawa</name></author><author><name sortKey="Sakakibara, K" uniqKey="Sakakibara K">K Sakakibara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kajiyama, H" uniqKey="Kajiyama H">H Kajiyama</name></author><author><name sortKey="Shibata, K" uniqKey="Shibata K">K Shibata</name></author><author><name sortKey="Mizuno, M" uniqKey="Mizuno M">M Mizuno</name></author><author><name sortKey="Hosono, S" uniqKey="Hosono S">S Hosono</name></author><author><name sortKey="Kawai, M" uniqKey="Kawai M">M Kawai</name></author><author><name sortKey="Nagasaka, T" uniqKey="Nagasaka T">T Nagasaka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zanetta, G" uniqKey="Zanetta G">G Zanetta</name></author><author><name sortKey="Chiari, S" uniqKey="Chiari S">S Chiari</name></author><author><name sortKey="Rota, S" uniqKey="Rota S">S Rota</name></author><author><name sortKey="Bratina, G" uniqKey="Bratina G">G Bratina</name></author><author><name sortKey="Maneo, A" uniqKey="Maneo A">A Maneo</name></author><author><name sortKey="Torri, V" uniqKey="Torri V">V Torri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schilder, Jm" uniqKey="Schilder J">JM Schilder</name></author><author><name sortKey="Thompson, Am" uniqKey="Thompson A">AM Thompson</name></author><author><name sortKey="Depriest, Pd" uniqKey="Depriest P">PD DePriest</name></author><author><name sortKey="Ueland, Fr" uniqKey="Ueland F">FR Ueland</name></author><author><name sortKey="Cibull, Ml" uniqKey="Cibull M">ML Cibull</name></author><author><name sortKey="Kryscio, Rj" uniqKey="Kryscio R">RJ Kryscio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morice, P" uniqKey="Morice P">P Morice</name></author><author><name sortKey="Leblanc, E" uniqKey="Leblanc E">E Leblanc</name></author><author><name sortKey="Rey, A" uniqKey="Rey A">A Rey</name></author><author><name sortKey="Baron, M" uniqKey="Baron M">M Baron</name></author><author><name sortKey="Querleu, D" uniqKey="Querleu D">D Querleu</name></author><author><name sortKey="Blanchot, J" uniqKey="Blanchot J">J Blanchot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Satoh, T" uniqKey="Satoh T">T Satoh</name></author><author><name sortKey="Hatae, M" uniqKey="Hatae M">M Hatae</name></author><author><name sortKey="Watanabe, Y" uniqKey="Watanabe Y">Y Watanabe</name></author><author><name sortKey="Yaegashi, N" uniqKey="Yaegashi N">N Yaegashi</name></author><author><name sortKey="Ishiko, O" uniqKey="Ishiko O">O Ishiko</name></author><author><name sortKey="Kodama, S" uniqKey="Kodama S">S Kodama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sugiyama, T" uniqKey="Sugiyama T">T Sugiyama</name></author><author><name sortKey="Okamoto, A" uniqKey="Okamoto A">A Okamoto</name></author><author><name sortKey="Enomoto, T" uniqKey="Enomoto T">T Enomoto</name></author><author><name sortKey="Hamano, T" uniqKey="Hamano T">T Hamano</name></author><author><name sortKey="Aotani, E" uniqKey="Aotani E">E Aotani</name></author><author><name sortKey="Terao, Y" uniqKey="Terao Y">Y Terao</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Gynecol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Gynecol Oncol</journal-id><journal-id journal-id-type="publisher-id">JGO</journal-id><journal-title-group><journal-title>Journal of Gynecologic Oncology</journal-title></journal-title-group><issn pub-type="ppub">2005-0380</issn><issn pub-type="epub">2005-0399</issn><publisher><publisher-name>Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28541641</article-id><article-id pub-id-type="pmc">5447152</article-id><article-id pub-id-type="doi">10.3802/jgo.2017.28.e54</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jang</surname><given-names>Ji Yon Agnes</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0160-7085</contrib-id><name><surname>Yanaihara</surname><given-names>Nozomu</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pujade-Lauraine</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mikami</surname><given-names>Yoshiki</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Oda</surname><given-names>Katsutoshi</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bookman</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ledermann</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Muneaki</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kiyokawa</surname><given-names>Takako</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0572-8450</contrib-id><name><surname>Kim</surname><given-names>Byoung-Gie</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Matsumura</surname><given-names>Noriomi</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kaku</surname><given-names>Tsunehisa</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2659-1449</contrib-id><name><surname>Kuroda</surname><given-names>Takafumi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nagayoshi</surname><given-names>Yoko</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5220-4409</contrib-id><name><surname>Kawabata</surname><given-names>Ayako</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Iida</surname><given-names>Yasushi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1835-9436</contrib-id><name><surname>Kim</surname><given-names>Jae-Weon</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5079-0464</contrib-id><name><surname>Okamoto</surname><given-names>Aikou</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</aff><aff id="A2"><label>2</label>Unité Cancer de la Femme et Recherche Clinique, Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, Université Paris Descartes, Paris,<country>France</country>.</aff><aff id="A3"><label>3</label>Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto,<country>Japan</country>.</aff><aff id="A4"><label>4</label>Department of Obstetrics and Gynecology, Graduate School of Medicine, University of Tokyo, Tokyo,<country>Japan</country>.</aff><aff id="A5"><label>5</label>US Oncology Research and Arizona Oncology, Tucson, AZ,<country>USA</country>.</aff><aff id="A6"><label>6</label>UCL Cancer Institute, University College London, London,<country>UK</country>.</aff><aff id="A7"><label>7</label>Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago,<country>Japan</country>.</aff><aff id="A8"><label>8</label>Department of Pathology, The Jikei University School of Medicine, Tokyo,<country>Japan</country>.</aff><aff id="A9"><label>9</label>Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,<country>Korea</country>.</aff><aff id="A10"><label>10</label>Department of Obstetrics and Gynecology, Kyoto University, Kyoto,<country>Japan</country>.</aff><aff id="A11"><label>11</label>Department of Health Sciences, Graduate School of Medical Science, Kyushu University, Fukuoka,<country>Japan</country>.</aff><aff id="A12"><label>12</label>Department of Obstetrics and Gynecology, Seoul National University, Seoul,<country>Korea</country>.</aff><aff id="A13"><label>13</label>Women's Cancer Research Center, Royal Women's Hospital, Melbourne,<country>Australia</country>.</aff><author-notes><corresp>Correspondence to Nozomu Yanaihara. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan. <email>yanazou@jikei.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>01</day><month>5</month><year>2017</year></pub-date><volume>28</volume><issue>4</issue><elocation-id>e54</elocation-id><history><date date-type="received"><day>02</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>17</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).</p></abstract><kwd-group kwd-group-type="author"><kwd>Rare Diseases</kwd><kwd>Ovarian Neoplasms</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>At the Rare Ovarian Tumors Conference held in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG), young investigators addressed an update on recent advances in the knowledge and treatment of rare ovarian cancers, including low-grade serous, mucinous, and clear cell carcinomas of the ovary.</p></sec><sec><title>LOW-GRADE SEROUS CARCINOMA (LGSC)</title><sec id="sec1"><title>1. Background</title><p>Recent studies have identified low-grade and high-grade serous carcinomas (HGSC) as 2 distinct entities and the new edition of the World Health Organization (WHO) classification, published in 2014, has adopted this binary classification. Traditional 3-tiered grading of serous carcinoma had limited significance in terms of prognosis, management strategies, and biology, whereas the 2-tier system well reflects the molecular pathogenesis, clinicopathologic features, and epidemiology. These criteria for grading, established by Malpica et al. [<xref rid="B1" ref-type="bibr">1</xref>], have now been widely accepted. LGSC defined as serous carcinoma composed of uniform cells showing mild to moderate nuclear atypia and fewer mitotic figures (12 or less, and in general, mostly 2 to 3 per 10 high power fields [HPFs]), is a rare neoplasm accounting for 5%–10% of all ovarian serous carcinomas. Very rarely, LGSC may give rise to HGSC or undifferentiated carcinoma [<xref rid="B2" ref-type="bibr">2</xref>].</p></sec><sec id="sec2"><title>2. Understanding the difference between LGSC and HGSC</title><p>LGSC and HGSC differ distinctly in presentation, histogenesis, treatment strategies, and outcome (<xref ref-type="table" rid="T1">Table 1</xref>). The former is characterised by younger age, and paradoxically, poor response to conventional chemotherapy [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref>]. It is mitotically less active, and immunohistochemically shows a low Ki-67 labelling index. Since <italic>TP53</italic> is typically intact, <italic>TP53</italic> immunostaining shows wild-type pattern, aiding distinction of LGSC from HGSC. <italic>KRAS</italic>, <italic>BRAF</italic>, or <italic>ERBB2</italic> mutations are common in contrast to HGSC, which is characterised nearly uniform loss of <italic>TP53</italic> function due to mutation or deletion, associated with significant chromosomal instability and decreased overall survival (OS) [<xref rid="B8" ref-type="bibr">8</xref>].</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Differentiating low- and high-grade serous carcinoma</title></caption><alternatives><graphic xlink:href="jgo-28-e54-i001"></graphic><table frame="hsides" rules="rows"><col width="29.01%" span="1"></col><col width="29.01%" span="1"></col><col width="29.01%" span="1"></col><col width="12.98%" span="1"></col><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Feature</th><th valign="top" align="center" rowspan="1" colspan="1">LGSC</th><th valign="top" align="center" rowspan="1" colspan="1">HGSC</th><th valign="top" align="center" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Nuclear atypia</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Uniform</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Pleomorphic</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B1" ref-type="bibr">1</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Form</td><td valign="top" align="left" rowspan="1" colspan="1">Oval/round</td><td valign="top" align="left" rowspan="1" colspan="1">Variable</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B1" ref-type="bibr">1</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Size and shape</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Uniform</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Variable (>3:1) in size</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B1" ref-type="bibr">1</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nucleoli</td><td valign="top" align="left" rowspan="1" colspan="1">May exist</td><td valign="top" align="left" rowspan="1" colspan="1">Present</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B1" ref-type="bibr">1</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Mitotic index/10 HPFs</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">≤12</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">>12</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B1" ref-type="bibr">1</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Precursor</td><td valign="top" align="left" rowspan="1" colspan="1">SBT</td><td valign="top" align="left" rowspan="1" colspan="1">STIC</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B7" ref-type="bibr">7</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Incidence</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">4%–10%</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">>85%</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B6" ref-type="bibr">6</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Median age</td><td valign="top" align="left" rowspan="1" colspan="1">Younger, <50 yr</td><td valign="top" align="left" rowspan="1" colspan="1">Older, >50 yr</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B6" ref-type="bibr">6</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Stage at presentation</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Early in about 40%</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Advanced in 70%–80%</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B6" ref-type="bibr">6</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clinical course</td><td valign="top" align="left" rowspan="1" colspan="1">Indolent</td><td valign="top" align="left" rowspan="1" colspan="1">Aggressive</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B6" ref-type="bibr">6</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Response to chemotherapy</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Usually poor</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Good but with high recurrence rate</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B5" ref-type="bibr">5</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chromosomal instability</td><td valign="top" align="left" rowspan="1" colspan="1">Low</td><td valign="top" align="left" rowspan="1" colspan="1">High</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B13" ref-type="bibr">13</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Gene mutation</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>KRAS</italic>, <italic>BRAF</italic>, and <italic>ERBB2</italic></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>TP53</italic></td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">[<xref rid="B8" ref-type="bibr">8</xref>]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5-yr survival</td><td valign="top" align="left" rowspan="1" colspan="1">50%–60%</td><td valign="top" align="left" rowspan="1" colspan="1">30%–40%</td><td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B15" ref-type="bibr">15</xref>]</td></tr></tbody></table></alternatives><table-wrap-foot><p>HGSC, high-grade serous carcinoma; HPF, high power field; LGSC, low-grade serous carcinoma; SBT, serous borderline tumor; STIC, serous tubal intraepithelial carcinoma.</p></table-wrap-foot></table-wrap><p>HGSC is considered to rise de novo in association with serous tubal intraepithelial carcinoma (STIC). On the other hand, LGSC appears to have a close phenotypic relationship to serous borderline tumors (SBT), particularly of the micropapillary type, because of similar cytomorphology, occasional co-existence of both borderline and low-grade components, and overexpression of <italic>CDKN1A</italic> and other <italic>TP53</italic> modulated genes [<xref rid="B9" ref-type="bibr">9</xref>] indicating the existence of adenoma-carcinoma sequence [<xref rid="B10" ref-type="bibr">10</xref>]. Therefore, the revised WHO classification (2014) specifically defines micropapillary SBT as non-invasive LGSC.</p><p>SBT shares a common high <italic>KRAS</italic> mutation rate with LGSC (20%–40% of cases), and much more frequently shows <italic>BRAF</italic> mutations compared with LGSC (30%–50% vs. 0%–30%) especially in advanced stages [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref><xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref>]. Deletion of tumor-suppressor function of <italic>miR-34a</italic> and <italic>CDKN2A/B</italic> has been suggested to be implicated in the progression of SBT to LGSC, although this finding remains to be confirmed by further evaluation [<xref rid="B12" ref-type="bibr">12</xref>]. The distinction between SBT and LGSC is critical for deciding on conservative or radical surgical management, since fertility is often a major concern in younger patients especially with bilateral disease [<xref rid="B13" ref-type="bibr">13</xref>]. A recent study has demonstrated that women below the age of 35 years with persistent disease at completion of initial therapy have a poorer outcome [<xref rid="B14" ref-type="bibr">14</xref>]. There has been a suggested association between an increased risk for developing LGSC in women who have a history of endometriosis [<xref rid="B15" ref-type="bibr">15</xref>].</p></sec><sec id="sec3"><title>3. Treatment targets</title><p>Traditional platinum-taxane combination chemotherapy has shown to have lower activity in LGSC compared to HGSC [<xref rid="B5" ref-type="bibr">5</xref>]. Commonly, primary cytoreductive surgery followed by adjuvant platinum based chemotherapy for advanced disease has been the standard practice in many countries despite limited evidence of benefit from chemotherapy [<xref rid="B16" ref-type="bibr">16</xref><xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">19</xref>]. Targeted therapies have, however, shown considerable promise, mainly in small non-randomized trials. Bevacizumab; Grisham et al. [<xref rid="B20" ref-type="bibr">20</xref>] performed a retrospective review of 17 patients who were treated with bevacizumab, 15 of whom were treated with combinations and 2 with bevacizumab alone. A partial response was obtained in 40% of the patient group (95% confidence interval [CI]=16.3%–67.7%). Similar results were obtained in a retrospective review performed by Schmeler et al. [<xref rid="B21" ref-type="bibr">21</xref>], with a response rate of 41% in a group of 21 patients. The value of bevacizumab in first-line treatment of serous ovarian cancers has been demonstrated in 2 phase III randomised studies; the GCIG International Collaboration on Ovarian Neoplasms 7 (ICON7) trial and the complementary Gynecologic Oncology Group study 0218 (GOG-0218) with promising results, however there were limited data in lower grade cancers (<xref ref-type="table" rid="T2">Table 2</xref>) [<xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref>]. For recurrent disease, surgery remains the most effective intervention, and should be performed whenever possible. Hormonal therapy; LGSC express higher levels of estrogen receptor (ER), progesterone receptor (PR), and E-cadherin than HGSC, suggesting the possibility of these receptors as potential targets of therapy [<xref rid="B24" ref-type="bibr">24</xref>] and treatment with tamoxifen and letrozole has been shown to provide clinical benefit in epithelial ovarian cancers overall [<xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">26</xref>]. A retrospective review of hormonal intervention suggested moderate anti-tumor activity in cases of recurrent LGSC with the median time to progression (TTP) being 7.4 months (95% CI=6.0–8.9 months), and that patients with both ER and PR double positive tumors had longer TTP than those who were PR negative. The study concluded that the stability of ER and PR in LGSC in the long term however was questionable and hence further studies are required [<xref rid="B27" ref-type="bibr">27</xref>]. Vemurafenib; the presence of V600E <italic>BRAF</italic> mutations, although low in incidence, is associated with an improved prognosis and is more frequently seen in early stage disease [<xref rid="B28" ref-type="bibr">28</xref>]. Treatment with vemurafenib, a <italic>BRAF</italic> inhibitor specific for V600E mutations has shown long term partial responses with improvement in both CA125 levels and in symptom control [<xref rid="B29" ref-type="bibr">29</xref>]. Mitogen-activated protein kinase kinase (MEK) inhibitors; Selumetinib (AZD6244, ARRY-142886) an orally available small molecule inhibitor of the MEK pathway was tested in a phase II clinical trial of 52 patients with LGSC. The median progression-free survival (PFS) was 11 months with a response rate of 15% (90% CI=7.9%–26.1%). The response to selumetinib did not appear to be related to <italic>RAS/RAF</italic> mutation status owing to significant tumor heterogeneity, and other factors that may contribute to pathway activation [<xref rid="B30" ref-type="bibr">30</xref>]. A randomized phase II/III trial is currently underway for trametinib, a MEK inhibitor, in recurrent or progressive low-grade serous ovarian cancer (GOG281), comparing the effectiveness of trametinib to chemotherapy chosen by the physician [<xref rid="B31" ref-type="bibr">31</xref>]. The MEK inhibitor in low-grade serous ovarian cancer (MILO) trial, an international, randomized phase III study of binimetinib or a chemotherapy chosen by a physician in patients with recurrent or persistent LGSC, was closed earlier after a planned interim analysis which showed that the hazard ratio for PFS crossed the predefined futility boundary [<xref rid="B32" ref-type="bibr">32</xref>]. Insulin-like growth factor 1 (IGF-1) pathway; IGF-1 is overexpressed in LGSC compared to SBT and HGSC and IGF-1 and Akt activation may be a potential drug target in the future [<xref rid="B33" ref-type="bibr">33</xref>]. Phase II trials are currently underway with the anti-IGF-1R monoclonal antibodies figitumumab (CP-751871) and ganitumab (AMG479) in epithelial ovarian cancer.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Bevacizumab in low- and high-grade serous carcinoma</title></caption><alternatives><graphic xlink:href="jgo-28-e54-i002"></graphic><table frame="hsides" rules="rows"><col width="3.95%" span="1"></col><col width="28.95%" span="1"></col><col width="33.55%" span="1"></col><col width="33.55%" span="1"></col><thead><tr><th valign="top" align="left" rowspan="1" colspan="2">Trial</th><th valign="top" align="center" rowspan="1" colspan="1">No. of patients</th><th valign="top" align="center" rowspan="1" colspan="1">HR</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="2" style="background-color:rgb(254,239,212)">GOG-0218 [<xref rid="B22" ref-type="bibr">22</xref>]</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Low-grade</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">235</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">0.59</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">High-grade</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">842</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">0.70</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">ICON7 [<xref rid="B23" ref-type="bibr">23</xref>]</td><td valign="top" align="right" rowspan="1" colspan="1"></td><td valign="top" align="right" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Grade 1</td><td valign="top" align="right" rowspan="1" colspan="1">97</td><td valign="top" align="right" rowspan="1" colspan="1">0.76</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Grade 2</td><td valign="top" align="right" rowspan="1" colspan="1">317</td><td valign="top" align="right" rowspan="1" colspan="1">0.77</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Grade 3</td><td valign="top" align="right" rowspan="1" colspan="1">1,094</td><td valign="top" align="right" rowspan="1" colspan="1">0.81</td></tr></tbody></table></alternatives><table-wrap-foot><p>GOG, Gynecologic Oncology Group; HR, hazard ratio; ICON7, International Collaboration on Ovarian Neoplasms 7.</p></table-wrap-foot></table-wrap></sec><sec id="sec4"><title>4. Take home message</title><p>As LGSC demonstrates distinct clinicopathologic and molecular features, it should be distinguished from HGSC in future clinical trials with translational components incorporated into their design. International cooperation will be required to establish strategies employing targeted agents as well as defining effective prognostic and predictive biomarkers. Finally, gynaecologic oncologists should be aware of the rare coexistence or progression to HGSC in cases of LGSC or SBT which can be a pitfall in management.</p></sec></sec><sec><title>MUCINOUS CARCINOMA</title><sec id="sec1___1"><title>1. Background</title><p>Ovarian mucinous carcinoma (OMC) is defined as an epithelial tumor with frank invasion (the largest invasive area equal to or greater than 5 mm) composed of gastrointestinal-type cells containing intracytoplasmic mucin. Recent studies have revealed that primary OMCs are much less common than previously reported (2%–3% of primary ovarian carcinomas), and that those reported as primary OMCs in the past likely included some metastatic tumors as well as mucinous borderline tumors [<xref rid="B34" ref-type="bibr">34</xref><xref rid="B35" ref-type="bibr">35</xref>]. There are 2 types of invasion in OMCs, expansile (or confluent glandular) and infiltrative, which may coexist in a single tumor (<xref ref-type="table" rid="T3">Table 3</xref>). The pathological distinction of pattern of invasion is important, as there is significant difference in prognosis between those with confluent and infiltrative type of invasion. Majority of OMCs are with expansile invasion, almost always stage I, and are usually associated with a favourable prognosis [<xref rid="B36" ref-type="bibr">36</xref><xref rid="B37" ref-type="bibr">37</xref><xref rid="B38" ref-type="bibr">38</xref>]. In contrast, about 80% of OMCs with infiltrative invasion are stage I, 20% of which recur. Recurrences tend to occur within 3 years of diagnosis and do not respond to chemotherapy or radiotherapy.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Classification of mucinous tumors of the ovary</title></caption><alternatives><graphic xlink:href="jgo-28-e54-i003"></graphic><table frame="hsides" rules="rows"><col width="50%" span="1"></col><col width="50%" span="1"></col><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Type</th><th valign="top" align="center" rowspan="1" colspan="1">Subtype</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="3" colspan="1" style="background-color:rgb(254,239,212)">Benign</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"> </td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Cystadenoma</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Cystadenofibroma</td></tr><tr><td valign="top" align="left" rowspan="4" colspan="1">Borderline</td><td valign="top" align="left" rowspan="1" colspan="1"> </td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Borderline with intraepithelial atypia</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Borderline with microinvasion <5 mm</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Borderline with microinvasive carcinoma</td></tr><tr><td valign="top" align="left" rowspan="3" colspan="1" style="background-color:rgb(254,239,212)">Carcinoma (frank invasion ≥5 mm)</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"> </td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Confluent type</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Infiltrative type</td></tr></tbody></table></alternatives></table-wrap><p>Distinction between primary OMCs and metastatic tumors may be pathologically challenging, although careful gross examination and thorough sampling of the tumor with assistance of immunohistochemistry in certain situation could lead to a correct diagnosis in many of the cases. Those with bilaterality, small size (<10 cm in diameter), high-stage, and an infiltrative invasion should raise suspicion for metastatic tumors [<xref rid="B34" ref-type="bibr">34</xref><xref rid="B39" ref-type="bibr">39</xref><xref rid="B40" ref-type="bibr">40</xref><xref rid="B41" ref-type="bibr">41</xref>]. The pathological features that favour primary mucinous tumors include: size >10 cm in diameter, multilocular cystic and/or solid tumor without multiple nodules, smooth external surface, expansile pattern of invasion, complex papillary pattern, coexistence of borderline or benign components, an association with a teratoma, endometriosis, adenofibroma, Brenner tumor, or mural nodule. Because OMCs typically form large cystic masses with or without solid component and are frequently admixed with benign and borderline components, sampling is crucial for accurate pathological diagnosis of OMCs. The number of the sections recommended is at least one per centimetre of maximum tumor dimension for tumor smaller than 10 cm, and 2 sections per centimetre for larger tumors [<xref rid="B41" ref-type="bibr">41</xref>].</p></sec><sec id="sec2___1"><title>2. Dilemmas in diagnosis and management</title><p>A small portion of advanced-stage mucinous tumors of the ovary are primary in origin (20%) and most are metastatic tumors from the gastrointestinal tract (45%), pancreas (20%), cervix (13%), breast (8%), uterus (5%), or unknown (10%) [<xref rid="B35" ref-type="bibr">35</xref>]. Clinicians face great challenge in pathologically distinguishing a primary mucinous tumor of ovarian origin from a metastatic tumor. In this case, molecular and clinical features may aid in distinguishing the two (<xref ref-type="table" rid="T4">Table 4</xref>) [<xref rid="B40" ref-type="bibr">40</xref><xref rid="B41" ref-type="bibr">41</xref><xref rid="B42" ref-type="bibr">42</xref><xref rid="B43" ref-type="bibr">43</xref><xref rid="B44" ref-type="bibr">44</xref><xref rid="B45" ref-type="bibr">45</xref>]. A retrospective analysis of GOG182/ICON5 on independent review of 44 stage III/IV mucinous carcinomas of the ovary by 3 different pathologists, showed that median survival did not differ greatly between primary or metastatic groups. However, many of those mucinous carcinomas that were initially diagnosed as primary OMC appeared to be metastatic in origin [<xref rid="B46" ref-type="bibr">46</xref>].</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Differentiating mucinous carcinomas of primary vs. metastatic origin</title></caption><alternatives><graphic xlink:href="jgo-28-e54-i004"></graphic><table frame="hsides" rules="rows"><col width="19.08%" span="1"></col><col width="40.46%" span="1"></col><col width="40.46%" span="1"></col><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Feature</th><th valign="top" align="center" rowspan="1" colspan="1">Primary</th><th valign="top" align="center" rowspan="1" colspan="1">Metastatic</th></tr></thead><tbody><tr><td valign="top" align="justify" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Pathological pattern</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Intracellular mucin (>50%), in at least 90% of tumor cells<break></break>Complex papillary pattern</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Abundant extracellular mucin, in 50% or greater tumor volume<break></break>Nodular pattern</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1">Involvement</td><td valign="top" align="left" rowspan="1" colspan="1">Coexistence of borderline/benign mucinous component<break></break>Expansile pattern of invasion</td><td valign="top" align="left" rowspan="1" colspan="1">Ovarian surface involvement<break></break>Hilar involvement<break></break>Vascular invasion<break></break>Extensive infiltrative pattern of invasion</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Size and distribution</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Unilateral<break></break>Size >10 cm</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Bilateral<break></break>Size <10 cm</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1">Markers</td><td valign="top" align="left" rowspan="1" colspan="1">CA125<break></break>CEA >25</td><td valign="top" align="left" rowspan="1" colspan="1">Elevation may be present, although less than in colorectal primary cancers</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Molecular alterations</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>KRAS</italic> mutations: 43%<break></break><italic>BRAF</italic> mutations: 0%<break></break><italic>HER2</italic> amplification: 18%</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>KRAS</italic> mutations: 30%<break></break><italic>BRAF</italic> mutations: 20%<break></break><italic>HER2</italic> amplification: <1%</td></tr></tbody></table></alternatives><table-wrap-foot><p>CEA, carcinoembryonic antigen; <italic>HER2</italic>, human epidermal growth factor receptor 2.</p></table-wrap-foot></table-wrap><p>As most OMCs present with localized disease (more than 80% of OMCs are stage I at the time of diagnosis), the standard treatment for patients with early mucinous carcinomas is cytoreductive surgery with pathological evaluation accompanied by surgical staging and special attention to possible gastrointestinal sites of primary disease. Nodal staging is not required in stage IA/IB due to the almost absence of nodal involvement. In younger patients with unilateral early stage disease it is reasonable to consider fertility sparing surgery. Furthermore, there is no clear evidence to suggest that adjuvant chemotherapy is beneficial in the setting of early stage disease. There is limited evidence for the effectiveness of systemic therapy in late stage OMCs. Most notably, only 2%–7% of patients in large randomized controlled trials had mucinous carcinomas. A retrospective review by Winter et al. [<xref rid="B47" ref-type="bibr">47</xref>] which investigated the effects of platinum/paclitaxel post debulking surgery in the mucinous cancer group, showed a median OS of 14.8 months comparable to 45.1 months in the serous group. Mimicking Winter's study, results produced by the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO), GOG, and GCIG group have yielded similar results (<xref ref-type="table" rid="T5">Table 5</xref>) [<xref rid="B48" ref-type="bibr">48</xref><xref rid="B49" ref-type="bibr">49</xref><xref rid="B50" ref-type="bibr">50</xref>].</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Comparison of OS and PFS in OMC compared to serous ovarian carcinoma</title></caption><alternatives><graphic xlink:href="jgo-28-e54-i005"></graphic><table frame="hsides" rules="rows"><col width="3.7%" span="1"></col><col width="29.01%" span="1"></col><col width="33.64%" span="1"></col><col width="33.64%" span="1"></col><thead><tr><th valign="top" align="left" rowspan="1" colspan="2">Study</th><th valign="top" align="center" rowspan="1" colspan="1">Median OS (mon)</th><th valign="top" align="center" rowspan="1" colspan="1">Median PFS (mon)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="2" style="background-color:rgb(254,239,212)">Winter et al. [<xref rid="B47" ref-type="bibr">47</xref>]</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Serous</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">45.1</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">16.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Mucinous</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">14.8</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">10.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Alexandre et al. [<xref rid="B48" ref-type="bibr">48</xref>]</td><td valign="top" align="right" rowspan="1" colspan="1"></td><td valign="top" align="right" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Serous</td><td valign="top" align="right" rowspan="1" colspan="1">47.2</td><td valign="top" align="right" rowspan="1" colspan="1">17.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Mucinous</td><td valign="top" align="right" rowspan="1" colspan="1">21.6</td><td valign="top" align="right" rowspan="1" colspan="1">11.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2" style="background-color:rgb(254,239,212)">Tian et al. [<xref rid="B49" ref-type="bibr">49</xref>]</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Serous</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">40.5</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">16.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"></td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">Mucinous</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">11.3</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">9.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="2">Mackay et al. [<xref rid="B50" ref-type="bibr">50</xref>]</td><td valign="top" align="right" rowspan="1" colspan="1"></td><td valign="top" align="right" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Serous</td><td valign="top" align="right" rowspan="1" colspan="1">40.8</td><td valign="top" align="right" rowspan="1" colspan="1">16.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Mucinous</td><td valign="top" align="right" rowspan="1" colspan="1">14.6</td><td valign="top" align="right" rowspan="1" colspan="1">7.6</td></tr></tbody></table></alternatives><table-wrap-foot><p>OMC, ovarian mucinous carcinoma; OS, overall survival; PFS, progression-free survival.</p></table-wrap-foot></table-wrap><p>Disappointing results with first line platinum-based chemotherapy in OMCs have prompted research into specific targeted therapy such as agents that act on the human epidermal growth factor receptor 2 (<italic>HER2</italic>)/<italic>neu</italic>, <italic>KRAS</italic>, or angiogenesis pathways. A phase III study of carboplatin/paclitaxel vs. oxaliplatin/capecitabine with or without bevacizumab showed hope that bevacizumab may delay progression; however, the study was stopped early due to poor accrual of patients [<xref rid="B51" ref-type="bibr">51</xref>]. Molecular characterisation of mucinous ovarian tumors has shown overexpression of <italic>HER2</italic> in 19% of cases with perfect agreement on immunohistochemistry, fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) [<xref rid="B52" ref-type="bibr">52</xref>]. A higher incidence of <italic>HER2</italic> overexpression in the Asian population has been postulated by Chay et al. [<xref rid="B53" ref-type="bibr">53</xref>], and whilst the impact of <italic>HER2</italic> status on OS is yet to be clearly established, anti-<italic>HER2</italic> therapy in combination with other agents may have a role in management [<xref rid="B54" ref-type="bibr">54</xref><xref rid="B55" ref-type="bibr">55</xref>].</p></sec><sec id="sec3___1"><title>3. Take home message</title><p>It is unfortunate that large trials for mucinous carcinomas in the international setting have been largely unsuccessful, and the best treatment is still unknown. As mucinous carcinomas have been shown to harbour a variety of molecular changes, the efficacy of single agent targeted therapy may be limited. Moreover, it is difficult to design adequately powered randomized controlled trials in cancers of such rare histological subtype. It will be important to use innovative trial designs to overcome this difficulty.</p></sec></sec><sec><title>CLEAR CELL CARCINOMA</title><sec id="sec1___2"><title>1. Background</title><p>Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian carcinoma which is distinct from HGSC, associated with poor prognosis in advanced stages and has been shown to be resistant to conventional platinum-based chemotherapy [<xref rid="B56" ref-type="bibr">56</xref>]. It accounts for 5%–25% of epithelial ovarian cancers with a higher incidence seen in Eastern-Asian women. Women with OCCC usually present early with 57%–81% presentations in stage I or II, and are younger (median age 55 years) and the disease is commonly associated with endometriosis. Hypercalcaemia and an increased incidence of venous thrombotic events may occur [<xref rid="B57" ref-type="bibr">57</xref>].</p><p>Histological features of OCCC include a variety of growth patterns (micropapillary, tubulocystic, solid, and adenofibromatous), cell types (hobnail, clear cell, and oxyphilic), stromal changes (hyalinized, necrotic, hemorrhagic, and psammomatous calcification), and the presence of endometriosis, atypical endometriosis, and atypical proliferative clear cell tumors [<xref rid="B58" ref-type="bibr">58</xref><xref rid="B59" ref-type="bibr">59</xref><xref rid="B60" ref-type="bibr">60</xref>]. These histological features often co-exist in the one tumor. Serous or endometrioid carcinoma frequently demonstrates cytoplasmic clearing (clear cell change), which leads to difficulty in accurate diagnoses of OCCC. A mitotic count greater than 5 per 10 HPFs is almost never encountered, with most tumors having mitotic counts between 0 and 2 per 10 HPFs [<xref rid="B59" ref-type="bibr">59</xref>]. The tumor arises from endometriosis in 50%–70% of cases [<xref rid="B58" ref-type="bibr">58</xref>]. An adenofibromatous pattern is present in 20%–25% of cases, and stromal hyalinization is one of the characteristic features [<xref rid="B58" ref-type="bibr">58</xref><xref rid="B59" ref-type="bibr">59</xref>].</p></sec><sec id="sec2___2"><title>2. Molecular changes in OCCC and translational possibilities</title><p>The molecular pathogenesis of OCCC is less well characterised than HGSC, however many studies show that it harbors unique molecular features including the AT-rich interactive domain 1A (<italic>ARID1A</italic>) gene mutation, hepatocyte nuclear factor-1β (HNF-1β) overexpression, and the phosphatidylinositol-4,5-bisphosphate 3-kinase (<italic>PIK3CA</italic>) mutation (<xref ref-type="table" rid="T6">Table 6</xref>) [<xref rid="B61" ref-type="bibr">61</xref><xref rid="B62" ref-type="bibr">62</xref>]. <italic>ARID1A</italic> encodes a key component of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodelling complex that regulates gene expression targeting multiple pathways that lead to tumorigenesis. It acts as a tumor-suppressor gene in OCCC and is seen in pre-neoplastic lesions leading to the speculation that this gene is implicated in the early transformation of endometriotic cells into cancer. It has been identified in up to 57% of cases of OCCC however no distinct phenotypical property has been identified that may contribute to increased survival [<xref rid="B63" ref-type="bibr">63</xref><xref rid="B64" ref-type="bibr">64</xref><xref rid="B65" ref-type="bibr">65</xref><xref rid="B66" ref-type="bibr">66</xref>]. HNF-1β is a transcription factor with predominant expression in liver, pancreas, and kidney and is known as a hallmark of OCCC. HNF-1β plays multiple roles in tumorigenesis and chemoresistance by alteration of glycolytic processes in OCCC cells, and by reducing oxidative phosphorylation and thus intracellular reactive oxygen species. Anti-stress properties that allow the survival of endometrial cells induce HNF-1β in the microenvironment and this is maintained throughout its cell life into malignant proliferation. This conferred stress resistance may contribute to the chemoresistance of OCCC [<xref rid="B67" ref-type="bibr">67</xref><xref rid="B68" ref-type="bibr">68</xref>]. <italic>PIK3CA</italic> mutations play an important role in the pathogenesis of OCCC with mutations seen in up to 42% of cases. <italic>PIK3CA</italic> activation results in abnormal cellular growth, proliferation, survival, and angiogenesis via complex intracellular networks in the regulation of tumor stem cells. <italic>PIK3CA</italic> mutations have been associated with favourable OS in OCCC in a mutational analysis of 56 primary OCCC cases in Japanese women [<xref rid="B69" ref-type="bibr">69</xref><xref rid="B70" ref-type="bibr">70</xref><xref rid="B71" ref-type="bibr">71</xref><xref rid="B72" ref-type="bibr">72</xref>]. Vascular endothelial growth factor (VEGF) overexpression is commonly seen in advanced stage epithelial ovarian cancer and is often associated with a poorer prognosis [<xref rid="B73" ref-type="bibr">73</xref><xref rid="B74" ref-type="bibr">74</xref>]. With its critical role in angiogenesis, this overexpression may be a therapeutic target and in vitro studies have been promising, showing inhibition of OCCC cell growth especially in cisplatin-refractory cases, highlighting its potential role in recurrent disease [<xref rid="B75" ref-type="bibr">75</xref>].</p><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Summary of mutated genes in OCCC [<xref rid="B61" ref-type="bibr">61</xref><xref rid="B62" ref-type="bibr">62</xref><xref rid="B63" ref-type="bibr">63</xref><xref rid="B64" ref-type="bibr">64</xref><xref rid="B65" ref-type="bibr">65</xref><xref rid="B66" ref-type="bibr">66</xref><xref rid="B67" ref-type="bibr">67</xref><xref rid="B68" ref-type="bibr">68</xref><xref rid="B69" ref-type="bibr">69</xref><xref rid="B70" ref-type="bibr">70</xref><xref rid="B71" ref-type="bibr">71</xref><xref rid="B72" ref-type="bibr">72</xref><xref rid="B73" ref-type="bibr">73</xref><xref rid="B74" ref-type="bibr">74</xref><xref rid="B75" ref-type="bibr">75</xref>]</title></caption><alternatives><graphic xlink:href="jgo-28-e54-i006"></graphic><table frame="hsides" rules="rows"><col width="34%" span="1"></col><col width="33%" span="1"></col><col width="33%" span="1"></col><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Type</th><th valign="top" align="center" rowspan="1" colspan="1">Gene</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency of mutation (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="3" colspan="1" style="background-color:rgb(254,239,212)">Oncogene</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>PIK3CA</italic></td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">54</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>KRAS</italic></td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)"><italic>PPP2R1A</italic></td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(254,239,212)">10</td></tr><tr><td valign="top" align="left" rowspan="6" colspan="1">Tumour suppressor</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ARID1A</italic></td><td valign="top" align="right" rowspan="1" colspan="1">62</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>MLL3</italic></td><td valign="top" align="right" rowspan="1" colspan="1">15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ARID1B</italic></td><td valign="top" align="right" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ASXL1</italic></td><td valign="top" align="right" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>CHD8</italic></td><td valign="top" align="right" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>PIK3R1</italic></td><td valign="top" align="right" rowspan="1" colspan="1">8</td></tr></tbody></table></alternatives><table-wrap-foot><p><italic>ARID1A</italic>, AT-rich interactive domain 1A; <italic>ARID1B</italic>, AT-rich interactive domain 1B; <italic>ASXL1</italic>, additional sex combs-like 1; <italic>CHD8</italic>, chromodomain helicase DNA binding protein 8; <italic>MLL3</italic>, mixed-lineage leukemia protein 3; OCCC, ovarian clear cell carcinoma; <italic>PIK3CA</italic>, phosphatidylinositol-4,5-bisphosphate 3-kinase; <italic>PPP2R1A</italic>, protein phosphatase 2 regulatory subunit A alpha.</p></table-wrap-foot></table-wrap></sec><sec id="sec3___2"><title>3. Controversies in the clinical management of OCCC</title><p>Women with OCCC present in early stages, and at a younger age, raising the question of the role of cytoreductive vs. fertility sparing surgery. Evidence to support complete surgical staging in early stage OCCC is lacking; however, the goal of primary surgical treatment in advanced disease should be complete cytoreduction. In the GOG study by Hoskins in 1994, mucinous and clear cell subtypes demonstrated a poor outcome despite small residual tumor size even after primary cytoreductive surgery [<xref rid="B76" ref-type="bibr">76</xref>]. A retrospective analysis of 254 patients showed that only primary cytoreduction which was complete contributed to a better in advanced cases [<xref rid="B77" ref-type="bibr">77</xref>]. On a similar note, the role of lymphadenectomy from a therapeutic perspective is unclear. It is acknowledged that the presence of lymph node metastases is an independent prognostic factor however it is not associated with OS on multivariate analysis [<xref rid="B78" ref-type="bibr">78</xref><xref rid="B79" ref-type="bibr">79</xref><xref rid="B80" ref-type="bibr">80</xref><xref rid="B81" ref-type="bibr">81</xref><xref rid="B82" ref-type="bibr">82</xref>]. Importantly, women undergoing fertility sparing surgery in OCCC did not show poorer survival than their non-OCCC counterparts [<xref rid="B83" ref-type="bibr">83</xref><xref rid="B84" ref-type="bibr">84</xref><xref rid="B85" ref-type="bibr">85</xref><xref rid="B86" ref-type="bibr">86</xref><xref rid="B87" ref-type="bibr">87</xref>].</p><p>OCCC demonstrates a lower response rate to platinum based chemotherapy compared to HGSC, with response rates of 11%–56% compared to 73%–81% in serous subtypes [<xref rid="B77" ref-type="bibr">77</xref>]. The Japanese Gynecologic Oncology Group (JGOG) undertook a randomized phase III trial (JGOG3017) of paclitaxel/carboplatin versus irinotecan/cisplatin as first-line chemotherapy in patients with stage IC–IV OCCC which showed no significant difference in 2-year PFS or OS [<xref rid="B88" ref-type="bibr">88</xref>], suggesting the need for an alternative approach such as targeted therapy.</p></sec><sec id="sec4___1"><title>4. Take home message</title><p>There are still significant gaps in our understanding of OCCC. The effect of hormonal status on malignant transformation is incompletely understood and the risks of subsequent malignancy in women with endometriosis remains unclear. A number of international trials have been designed with the aim of identifying molecular targets; however, it is acknowledged that the presence of such targets may not translate into the effectiveness of agents used to target them. Adequately powered trials with novel designs will be necessary to provide improved clinical outcomes for patients with these rare tumors.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Designing adequately powered studies to perform large scale randomized trials is the single largest barrier in improving understanding of rare epithelial ovarian cancers. International collaboration with multidisciplinary and translational components through groups such as the GCIG is required. Multiple smaller trials which screen agents for activity should be considered in the first instance, with expansion into larger randomized trials for agents that show promising activity. Additionally, the poor prognosis associated with many of these rare cancers at advanced stages signify the need for further research in developing novel methods for screening.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors acknowledge that all delegates to this conference, including all the staff members of the Obstetrics and Gynecology Department of The Jikei University School of Medicine.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="participating-researchers"><p><bold>Author Contributions:</bold><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> J.J.Y.A., Y.N., O.A.</p></list-item><list-item><p><bold>Formal analysis:</bold> J.J.Y.A., Y.N., P.L.E., M.Y., O.K., B.M., L.J., S.M., K.T., K.B.G., M.N., K.T.</p></list-item><list-item><p><bold>Funding acquisition:</bold> O.A.</p></list-item><list-item><p><bold>Investigation:</bold> J.J.Y.A., Y.N., P.L.E., M.Y., O.K., B.M., L.J., S.M., K.T., K.B.G., M.N., K.T.</p></list-item><list-item><p><bold>Methodology:</bold> P.L.E., M.Y., O.K., B.M., L.J., S.M., K.T., K.B.G., M.N., K.T.</p></list-item><list-item><p><bold>Supervision:</bold> K.J.W., Q.M., O.A.</p></list-item><list-item><p><bold>Validation:</bold> Y.N., K.T., N.Y., K.A., I.Y., K.J.W., Q.M., O.A.</p></list-item><list-item><p><bold>Writing - original draft:</bold> J.J.Y.A., Y.N., P.L.E., M.Y., O.K., B.M., L.J., S.M., K.T., K.B.G., M.N., K.T.</p></list-item><list-item><p><bold>Writing - review & editing:</bold> K.J.W., Q.M., O.A.</p></list-item></list></p></fn><fn fn-type="presented-at"><p>The contents of this article were presented in the Rare Ovarian Tumors Young Investigator Conference at The Jikei University School of Medicine, Tokyo, Japan on 6th November 2015.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Deavers</surname><given-names>MT</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Bodurka</surname><given-names>DC</given-names></name><name><surname>Atkinson</surname><given-names>EN</given-names></name><name><surname>Gershenson</surname><given-names>DM</given-names></name><etal></etal></person-group><article-title>Grading ovarian serous carcinoma using a two-tier system</article-title><source>Am J Surg Pathol</source><year>2004</year><volume>28</volume><fpage>496</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">15087669</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>C</given-names></name><name><surname>McCluggage</surname><given-names>WG</given-names></name></person-group><article-title>Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon</article-title><source>Am J Surg Pathol</source><year>2012</year><volume>36</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">22082603</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Sun</surname><given-names>CC</given-names></name><name><surname>Bodurka</surname><given-names>D</given-names></name><name><surname>Coleman</surname><given-names>RL</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><etal></etal></person-group><article-title>Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant</article-title><source>Gynecol Oncol</source><year>2009</year><volume>114</volume><fpage>48</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19361839</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Sun</surname><given-names>CC</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Coleman</surname><given-names>RL</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary</article-title><source>Obstet Gynecol</source><year>2006</year><volume>108</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">16880307</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmeler</surname><given-names>KM</given-names></name><name><surname>Sun</surname><given-names>CC</given-names></name><name><surname>Bodurka</surname><given-names>DC</given-names></name><name><surname>Deavers</surname><given-names>MT</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Coleman</surname><given-names>RL</given-names></name><etal></etal></person-group><article-title>Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum</article-title><source>Gynecol Oncol</source><year>2008</year><volume>108</volume><fpage>510</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">18155273</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plaxe</surname><given-names>SC</given-names></name></person-group><article-title>Epidemiology of low-grade serous ovarian cancer</article-title><source>Am J Obstet Gynecol</source><year>2008</year><volume>198</volume><fpage>459.e1</fpage><lpage>459.e8</lpage><pub-id pub-id-type="pmid">18395040</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindelberger</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Feltmate</surname><given-names>C</given-names></name><name><surname>Medeiros</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship</article-title><source>Am J Surg Pathol</source><year>2007</year><volume>31</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">17255760</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vang</surname><given-names>R</given-names></name><name><surname>Shih</surname><given-names>IM</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems</article-title><source>Adv Anat Pathol</source><year>2009</year><volume>16</volume><fpage>267</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">19700937</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonome</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>DC</given-names></name><name><surname>Radonovich</surname><given-names>M</given-names></name><name><surname>Pise-Masison</surname><given-names>C</given-names></name><name><surname>Brady</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>10602</fpage><lpage>10612</lpage><pub-id pub-id-type="pmid">16288054</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Shih</surname><given-names>IM</given-names></name></person-group><article-title>Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm</article-title><source>Hum Pathol</source><year>2011</year><volume>42</volume><fpage>918</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">21683865</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>IM</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis</article-title><source>Am J Pathol</source><year>2004</year><volume>164</volume><fpage>1511</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">15111296</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>KT</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jinawath</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>4036</fpage><lpage>4042</lpage><pub-id pub-id-type="pmid">19383911</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Pepa</surname><given-names>C</given-names></name><name><surname>Tonini</surname><given-names>G</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Losito</surname><given-names>S</given-names></name><name><surname>Pisano</surname><given-names>C</given-names></name><name><surname>Di Napoli</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy</article-title><source>Cancer Treat Rev</source><year>2015</year><volume>41</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">25573350</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Bodurka</surname><given-names>DC</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Nathan</surname><given-names>LC</given-names></name><name><surname>Milojevic</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><etal></etal></person-group><article-title>Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>2675</fpage><lpage>2682</lpage><pub-id pub-id-type="pmid">26195696</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>CL</given-names></name><name><surname>Templeman</surname><given-names>C</given-names></name><name><surname>Rossing</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Near</surname><given-names>AM</given-names></name><name><surname>Webb</surname><given-names>PM</given-names></name><etal></etal></person-group><article-title>Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">22361336</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bookman</surname><given-names>MA</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><name><surname>Harper</surname><given-names>PG</given-names></name><name><surname>Alberts</surname><given-names>DS</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>1419</fpage><lpage>1425</lpage><pub-id pub-id-type="pmid">19224846</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Rochon</surname><given-names>J</given-names></name><name><surname>Meier</surname><given-names>W</given-names></name><name><surname>Goupil</surname><given-names>A</given-names></name><name><surname>Olbricht</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">16505432</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoskins</surname><given-names>P</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><name><surname>Stuart</surname><given-names>G</given-names></name><name><surname>Zola</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><fpage>1547</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">20937992</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Reuss</surname><given-names>A</given-names></name><name><surname>Kimmig</surname><given-names>R</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>1036</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">16882940</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisham</surname><given-names>RN</given-names></name><name><surname>Iyer</surname><given-names>G</given-names></name><name><surname>Sala</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Iasonos</surname><given-names>A</given-names></name><name><surname>DeLair</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer</article-title><source>Int J Gynecol Cancer</source><year>2014</year><volume>24</volume><fpage>1010</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">24978709</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmeler</surname><given-names>KM</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>CC</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Deavers</surname><given-names>M</given-names></name><name><surname>Sood</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>abstr e15503</fpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Bookman</surname><given-names>MA</given-names></name><name><surname>Fleming</surname><given-names>GF</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Incorporation of bevacizumab in the primary treatment of ovarian cancer</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">22204724</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perren</surname><given-names>TJ</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Kristensen</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>A phase 3 trial of bevacizumab in ovarian cancer</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>2484</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">22204725</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Bodurka</surname><given-names>DC</given-names></name><name><surname>Shvartsman</surname><given-names>HS</given-names></name><name><surname>Schmandt</surname><given-names>RE</given-names></name><etal></etal></person-group><article-title>Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis</article-title><source>Int J Gynecol Pathol</source><year>2007</year><volume>26</volume><fpage>404</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">17885490</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirey</surname><given-names>DR</given-names></name><name><surname>Kavanagh</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Freedman</surname><given-names>RS</given-names></name><name><surname>Copeland</surname><given-names>LJ</given-names></name><name><surname>Jones</surname><given-names>LA</given-names></name></person-group><article-title>Tamoxifen therapy of epithelial ovarian cancer</article-title><source>Obstet Gynecol</source><year>1985</year><volume>66</volume><fpage>575</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">4047546</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>PT</given-names></name><name><surname>Schmeler</surname><given-names>KM</given-names></name><name><surname>Milam</surname><given-names>MR</given-names></name><name><surname>Slomovitz</surname><given-names>BM</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Kavanagh</surname><given-names>JJ</given-names></name><etal></etal></person-group><article-title>Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum</article-title><source>Gynecol Oncol</source><year>2008</year><volume>110</volume><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">18457865</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Sun</surname><given-names>CC</given-names></name><name><surname>Iyer</surname><given-names>RB</given-names></name><name><surname>Malpica</surname><given-names>AL</given-names></name><name><surname>Kavanagh</surname><given-names>JJ</given-names></name><name><surname>Bodurka</surname><given-names>DC</given-names></name><etal></etal></person-group><article-title>Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum</article-title><source>Gynecol Oncol</source><year>2012</year><volume>125</volume><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">22406638</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisham</surname><given-names>RN</given-names></name><name><surname>Iyer</surname><given-names>G</given-names></name><name><surname>Garg</surname><given-names>K</given-names></name><name><surname>DeLair</surname><given-names>D</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title><italic>BRAF</italic> mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">22930283</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combe</surname><given-names>P</given-names></name><name><surname>Chauvenet</surname><given-names>L</given-names></name><name><surname>Lefrère-Belda</surname><given-names>MA</given-names></name><name><surname>Blons</surname><given-names>H</given-names></name><name><surname>Rousseau</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Sustained response to vemurafenib in a low grade serous ovarian cancer with a <italic>BRAF</italic> V600E mutation</article-title><source>Invest New Drugs</source><year>2015</year><volume>33</volume><fpage>1267</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">26490654</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farley</surname><given-names>J</given-names></name><name><surname>Brady</surname><given-names>WE</given-names></name><name><surname>Vathipadiekal</surname><given-names>V</given-names></name><name><surname>Lankes</surname><given-names>HA</given-names></name><name><surname>Coleman</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">23261356</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="book"><collab>ClinicalTrials.gov (US)</collab><source>Trametinib in treating patients with recurrent or progressive low-grade ovarian cancer or peritoneal cavity cancer [Internet]</source><publisher-loc>Bethesda (MD)</publisher-loc><publisher-name>ClinicalTrials.gov</publisher-name><year>2014</year><date-in-citation content-type="access-date">cited 2014 Mar 28</date-in-citation><comment>Avaliable from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02101788">https://clinicaltrials.gov/ct2/show/NCT02101788</ext-link></comment></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="book"><collab>ClinicalTrials.gov (US)</collab><source>A study of MEK162 vs. Physician's choice chemotherapy in patients with low-grade serous ovarian, fallopian tube or peritoneal cancer [Internet]</source><publisher-loc>Bethesda (MD)</publisher-loc><publisher-name>ClinicalTrials.gov</publisher-name><year>2013</year><date-in-citation content-type="access-date">cited 2015 May 6</date-in-citation><comment>Avaliable from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01849874">https://clinicaltrials.gov/ct2/show/NCT01849874</ext-link></comment></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>ER</given-names></name><name><surname>Zu</surname><given-names>Z</given-names></name><name><surname>Tsang</surname><given-names>YT</given-names></name><name><surname>Deavers</surname><given-names>MT</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><etal></etal></person-group><article-title>The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma</article-title><source>Gynecol Oncol</source><year>2011</year><volume>123</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">21726895</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidman</surname><given-names>JD</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Ronnett</surname><given-names>BM</given-names></name></person-group><article-title>Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis</article-title><source>Am J Surg Pathol</source><year>2003</year><volume>27</volume><fpage>985</fpage><lpage>993</lpage><pub-id pub-id-type="pmid">12826891</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>M</given-names></name><name><surname>Kigawa</surname><given-names>J</given-names></name><name><surname>Ohishi</surname><given-names>Y</given-names></name><name><surname>Yasuda</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Hiura</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Clinicopathological characteristics of mucinous adenocarcinoma of the ovary</article-title><source>Gynecol Oncol</source><year>2009</year><volume>113</volume><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">19275957</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KR</given-names></name><name><surname>Scully</surname><given-names>RE</given-names></name></person-group><article-title>Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’</article-title><source>Am J Surg Pathol</source><year>2000</year><volume>24</volume><fpage>1447</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">11075847</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez</surname><given-names>IM</given-names></name><name><surname>Prat</surname><given-names>J</given-names></name></person-group><article-title>Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas</article-title><source>Am J Surg Pathol</source><year>2002</year><volume>26</volume><fpage>139</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">11812936</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riopel</surname><given-names>MA</given-names></name><name><surname>Ronnett</surname><given-names>BM</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas</article-title><source>Am J Surg Pathol</source><year>1999</year><volume>23</volume><fpage>617</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">10366144</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khunamornpong</surname><given-names>S</given-names></name><name><surname>Suprasert</surname><given-names>P</given-names></name><name><surname>Pojchamarnwiputh</surname><given-names>S</given-names></name><name><surname>Na Chiangmai</surname><given-names>W</given-names></name><name><surname>Settakorn</surname><given-names>J</given-names></name><name><surname>Siriaunkgul</surname><given-names>S</given-names></name></person-group><article-title>Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality</article-title><source>Gynecol Oncol</source><year>2006</year><volume>101</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">16300822</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KR</given-names></name><name><surname>Young</surname><given-names>RH</given-names></name></person-group><article-title>The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases</article-title><source>Am J Surg Pathol</source><year>2003</year><volume>27</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">12604884</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frumovitz</surname><given-names>M</given-names></name><name><surname>Schmeler</surname><given-names>KM</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Gershenson</surname><given-names>DM</given-names></name></person-group><article-title>Unmasking the complexities of mucinous ovarian carcinoma</article-title><source>Gynecol Oncol</source><year>2010</year><volume>117</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">20332054</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>ES</given-names></name><name><surname>Bae</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name></person-group><article-title>Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality</article-title><source>J Korean Med Sci</source><year>2010</year><volume>25</volume><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">20119573</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda-Taniguchi</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Miyake</surname><given-names>T</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Yoshino</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Metastatic mucinous adenocarcinoma of the ovary is characterized by advanced patient age, small tumor size, and elevated serum CA125</article-title><source>Gynecol Obstet Invest</source><year>2011</year><volume>72</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">21893929</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Ronnett</surname><given-names>BM</given-names></name></person-group><article-title>Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary</article-title><source>Int J Gynecol Pathol</source><year>2005</year><volume>24</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">15626919</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>PB</given-names></name><name><surname>Derchain</surname><given-names>SF</given-names></name><name><surname>Andrade</surname><given-names>LA</given-names></name></person-group><article-title>Metastatic mucinous carcinomas in the ovary: a practical approach to diagnosis related to gross aspects and to immunohistochemical evaluation</article-title><source>Int J Gynecol Pathol</source><year>2012</year><volume>31</volume><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">22653343</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaino</surname><given-names>RJ</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Lele</surname><given-names>SM</given-names></name><name><surname>Michael</surname><given-names>H</given-names></name><name><surname>Greer</surname><given-names>B</given-names></name><name><surname>Bookman</surname><given-names>MA</given-names></name></person-group><article-title>Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">20862744</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>WE</given-names><suffix>3rd</suffix></name><name><surname>Maxwell</surname><given-names>GL</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Carlson</surname><given-names>JW</given-names></name><name><surname>Ozols</surname><given-names>RF</given-names></name><name><surname>Rose</surname><given-names>PG</given-names></name><etal></etal></person-group><article-title>Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>3621</fpage><lpage>3627</lpage><pub-id pub-id-type="pmid">17704411</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>J</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Selle</surname><given-names>F</given-names></name><name><surname>Floquet</surname><given-names>A</given-names></name><name><surname>Cottu</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><fpage>2377</fpage><lpage>2381</lpage><pub-id pub-id-type="pmid">20494964</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Markman</surname><given-names>M</given-names></name><name><surname>Zaino</surname><given-names>R</given-names></name><name><surname>Ozols</surname><given-names>RF</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><name><surname>Muggia</surname><given-names>FM</given-names></name><etal></etal></person-group><article-title>CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>1395</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">19195045</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>HJ</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>Reuss</surname><given-names>A</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><etal></etal></person-group><article-title>Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer</article-title><source>Int J Gynecol Cancer</source><year>2010</year><volume>20</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">20683400</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname><given-names>ME</given-names></name><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Brady</surname><given-names>WE</given-names></name><name><surname>Penson</surname><given-names>RT</given-names></name><name><surname>Zaino</surname><given-names>RJ</given-names></name><name><surname>McCluggage</surname><given-names>WG</given-names></name><etal></etal></person-group><article-title>Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC)</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>abstr 5528</fpage></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anglesio</surname><given-names>MS</given-names></name><name><surname>Kommoss</surname><given-names>S</given-names></name><name><surname>Tolcher</surname><given-names>MC</given-names></name><name><surname>Clarke</surname><given-names>B</given-names></name><name><surname>Galletta</surname><given-names>L</given-names></name><name><surname>Porter</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <italic>HER2</italic> targeting in 19% of carcinomas</article-title><source>J Pathol</source><year>2013</year><volume>229</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">22899400</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chay</surname><given-names>WY</given-names></name><name><surname>Chew</surname><given-names>SH</given-names></name><name><surname>Ong</surname><given-names>WS</given-names></name><name><surname>Busmanis</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Thung</surname><given-names>S</given-names></name><etal></etal></person-group><article-title><italic>HER2</italic> amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e61565</fpage><pub-id pub-id-type="pmid">23620766</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlpine</surname><given-names>JN</given-names></name><name><surname>Wiegand</surname><given-names>KC</given-names></name><name><surname>Vang</surname><given-names>R</given-names></name><name><surname>Ronnett</surname><given-names>BM</given-names></name><name><surname>Adamiak</surname><given-names>A</given-names></name><name><surname>Köbel</surname><given-names>M</given-names></name><etal></etal></person-group><article-title><italic>HER2</italic> overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><fpage>433</fpage><pub-id pub-id-type="pmid">20003286</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Kuo</surname><given-names>WH</given-names></name><name><surname>Chen</surname><given-names>FL</given-names></name><name><surname>Lee</surname><given-names>MY</given-names></name><name><surname>Ruan</surname><given-names>A</given-names></name><name><surname>Tyan</surname><given-names>YS</given-names></name><etal></etal></person-group><article-title>Identification of the coexisting <italic>HER2</italic> gene amplification and novel mutations in the <italic>HER2</italic> protein-overexpressed mucinous epithelial ovarian cancer</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><fpage>2388</fpage><lpage>2394</lpage><pub-id pub-id-type="pmid">21347793</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anglesio</surname><given-names>MS</given-names></name><name><surname>Carey</surname><given-names>MS</given-names></name><name><surname>Köbel</surname><given-names>M</given-names></name><name><surname>Mackay</surname><given-names>H</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name></person-group><article-title>Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010</article-title><source>Gynecol Oncol</source><year>2011</year><volume>121</volume><fpage>407</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">21276610</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Carmen</surname><given-names>MG</given-names></name><name><surname>Birrer</surname><given-names>M</given-names></name><name><surname>Schorge</surname><given-names>JO</given-names></name></person-group><article-title>Clear cell carcinoma of the ovary: a review of the literature</article-title><source>Gynecol Oncol</source><year>2012</year><volume>126</volume><fpage>481</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">22525820</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Kaku</surname><given-names>T</given-names></name><name><surname>Amada</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Hirakawa</surname><given-names>T</given-names></name><name><surname>Ariyoshi</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study</article-title><source>Gynecol Oncol</source><year>2000</year><volume>77</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">10785482</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kigawa</surname><given-names>J</given-names></name><name><surname>Kaku</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Silverberg</surname><given-names>SG</given-names></name></person-group><source>Atlas of clear cell carcinoma of the ovary: a pathological guide</source><publisher-loc>Tokyo</publisher-loc><publisher-name>Springer</publisher-name><year>2015</year></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Kamura</surname><given-names>T</given-names></name><name><surname>Kigawa</surname><given-names>J</given-names></name><name><surname>Terakawa</surname><given-names>N</given-names></name><name><surname>Kikuchi</surname><given-names>Y</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy</article-title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>2584</fpage><lpage>2589</lpage><pub-id pub-id-type="pmid">10861437</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gounaris</surname><given-names>I</given-names></name><name><surname>Brenton</surname><given-names>JD</given-names></name></person-group><article-title>Molecular pathogenesis of ovarian clear cell carcinoma</article-title><source>Future Oncol</source><year>2015</year><volume>11</volume><fpage>1389</fpage><lpage>1405</lpage><pub-id pub-id-type="pmid">25952785</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Takano</surname><given-names>M</given-names></name><name><surname>Iwaya</surname><given-names>K</given-names></name><name><surname>Tamai</surname><given-names>S</given-names></name><name><surname>Matsubara</surname><given-names>O</given-names></name></person-group><article-title><italic>PIK3CA</italic> mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma</article-title><source>J Pathol</source><year>2011</year><volume>225</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">21735444</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>BG</given-names></name><name><surname>Roberts</surname><given-names>CW</given-names></name></person-group><article-title>SWI/SNF nucleosome remodellers and cancer</article-title><source>Nat Rev Cancer</source><year>2011</year><volume>11</volume><fpage>481</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">21654818</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigetomi</surname><given-names>H</given-names></name><name><surname>Tsunemi</surname><given-names>T</given-names></name><name><surname>Haruta</surname><given-names>S</given-names></name><name><surname>Kajihara</surname><given-names>H</given-names></name><name><surname>Yoshizawa</surname><given-names>Y</given-names></name><name><surname>Tanase</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities</article-title><source>Cancer Invest</source><year>2012</year><volume>30</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">22530740</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><name><surname>Shih</surname><given-names>IM</given-names></name><name><surname>Mao</surname><given-names>TL</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Roden</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Frequent mutations of chromatin remodeling gene <italic>ARID1A</italic> in ovarian clear cell carcinoma</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>228</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">20826764</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samartzis</surname><given-names>EP</given-names></name><name><surname>Noske</surname><given-names>A</given-names></name><name><surname>Dedes</surname><given-names>KJ</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Imesch</surname><given-names>P</given-names></name></person-group><article-title><italic>ARID1A</italic> mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><fpage>18824</fpage><lpage>18849</lpage><pub-id pub-id-type="pmid">24036443</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Kondoh</surname><given-names>H</given-names></name><name><surname>Amano</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma</article-title><source>Mol Carcinog</source><year>2015</year><volume>54</volume><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">24105991</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Amano</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Konishi</surname><given-names>I</given-names></name></person-group><article-title>Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>30704</fpage><lpage>30714</lpage><pub-id pub-id-type="pmid">26375553</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>XY</given-names></name></person-group><article-title>PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application</article-title><source>Am J Cancer Res</source><year>2015</year><volume>5</volume><fpage>1602</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">26175931</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>K</given-names></name></person-group><article-title>PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer</article-title><source>Arch Gynecol Obstet</source><year>2014</year><volume>290</volume><fpage>1067</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">25086744</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabuchi</surname><given-names>S</given-names></name><name><surname>Kuroda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Sasano</surname><given-names>T</given-names></name></person-group><article-title>The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer</article-title><source>Gynecol Oncol</source><year>2015</year><volume>137</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">25677064</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Rahman</surname><given-names>MT</given-names></name><name><surname>Nakayama</surname><given-names>N</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><name><surname>Katagiri</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Clinicopathologic and biological analysis of <italic>PIK3CA</italic> mutation in ovarian clear cell carcinoma</article-title><source>Hum Pathol</source><year>2012</year><volume>43</volume><fpage>2197</fpage><lpage>2206</lpage><pub-id pub-id-type="pmid">22705003</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Wellman</surname><given-names>TL</given-names></name><name><surname>Lounsbury</surname><given-names>KM</given-names></name></person-group><article-title>VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><year>2003</year><volume>91</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">14675669</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>GK</given-names></name><name><surname>Maclean</surname><given-names>AB</given-names></name><name><surname>Elmasry</surname><given-names>K</given-names></name><name><surname>Wong te Fong</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>RW</given-names></name><name><surname>Rashid</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer</article-title><source>Angiogenesis</source><year>2011</year><volume>14</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">21221762</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabuchi</surname><given-names>S</given-names></name><name><surname>Kawase</surname><given-names>C</given-names></name><name><surname>Altomare</surname><given-names>DA</given-names></name><name><surname>Morishige</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Sawada</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary</article-title><source>Mol Cancer Ther</source><year>2010</year><volume>9</volume><fpage>2411</fpage><lpage>2422</lpage><pub-id pub-id-type="pmid">20663925</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoskins</surname><given-names>WJ</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Homesley</surname><given-names>HD</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name><name><surname>Berman</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>170</volume><fpage>974</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">8166218</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>M</given-names></name><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name></person-group><article-title>Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?</article-title><source>J Exp Clin Cancer Res</source><year>2012</year><volume>31</volume><fpage>53</fpage><pub-id pub-id-type="pmid">22655678</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuragi</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Oikawa</surname><given-names>M</given-names></name><name><surname>Okuyama</surname><given-names>K</given-names></name><name><surname>Fujino</surname><given-names>T</given-names></name><name><surname>Sagawa</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0)</article-title><source>Gynecol Oncol</source><year>2000</year><volume>79</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">11063653</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negishi</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>T</given-names></name><name><surname>Todo</surname><given-names>Y</given-names></name><name><surname>Ebina</surname><given-names>Y</given-names></name><name><surname>Watari</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer</article-title><source>Gynecol Oncol</source><year>2004</year><volume>94</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">15262135</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magazzino</surname><given-names>F</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Ottaiano</surname><given-names>A</given-names></name><name><surname>Gadducci</surname><given-names>A</given-names></name><name><surname>Pisano</surname><given-names>C</given-names></name><name><surname>Sorio</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study</article-title><source>Int J Gynecol Cancer</source><year>2011</year><volume>21</volume><fpage>1063</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">21633300</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JK</given-names></name><name><surname>Munro</surname><given-names>EG</given-names></name><name><surname>Cheung</surname><given-names>MK</given-names></name><name><surname>Husain</surname><given-names>A</given-names></name><name><surname>Teng</surname><given-names>NN</given-names></name><name><surname>Berek</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Association of lymphadenectomy and survival in stage I ovarian cancer patients</article-title><source>Obstet Gynecol</source><year>2007</year><volume>109</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17197582</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Kajiyama</surname><given-names>H</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Ino</surname><given-names>K</given-names></name><name><surname>Nawa</surname><given-names>A</given-names></name><name><surname>Sakakibara</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><fpage>1284</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">18356137</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajiyama</surname><given-names>H</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>M</given-names></name><name><surname>Hosono</surname><given-names>S</given-names></name><name><surname>Kawai</surname><given-names>M</given-names></name><name><surname>Nagasaka</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible?</article-title><source>Hum Reprod</source><year>2011</year><volume>26</volume><fpage>3297</fpage><lpage>3302</lpage><pub-id pub-id-type="pmid">22016417</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanetta</surname><given-names>G</given-names></name><name><surname>Chiari</surname><given-names>S</given-names></name><name><surname>Rota</surname><given-names>S</given-names></name><name><surname>Bratina</surname><given-names>G</given-names></name><name><surname>Maneo</surname><given-names>A</given-names></name><name><surname>Torri</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Conservative surgery for stage I ovarian carcinoma in women of childbearing age</article-title><source>Br J Obstet Gynaecol</source><year>1997</year><volume>104</volume><fpage>1030</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">9307530</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilder</surname><given-names>JM</given-names></name><name><surname>Thompson</surname><given-names>AM</given-names></name><name><surname>DePriest</surname><given-names>PD</given-names></name><name><surname>Ueland</surname><given-names>FR</given-names></name><name><surname>Cibull</surname><given-names>ML</given-names></name><name><surname>Kryscio</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy</article-title><source>Gynecol Oncol</source><year>2002</year><volume>87</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12468335</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morice</surname><given-names>P</given-names></name><name><surname>Leblanc</surname><given-names>E</given-names></name><name><surname>Rey</surname><given-names>A</given-names></name><name><surname>Baron</surname><given-names>M</given-names></name><name><surname>Querleu</surname><given-names>D</given-names></name><name><surname>Blanchot</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique)</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><fpage>1379</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">15817592</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Hatae</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Yaegashi</surname><given-names>N</given-names></name><name><surname>Ishiko</surname><given-names>O</given-names></name><name><surname>Kodama</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>1727</fpage><lpage>1732</lpage><pub-id pub-id-type="pmid">20194858</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>A</given-names></name><name><surname>Enomoto</surname><given-names>T</given-names></name><name><surname>Hamano</surname><given-names>T</given-names></name><name><surname>Aotani</surname><given-names>E</given-names></name><name><surname>Terao</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG Trial</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>2881</fpage><lpage>2887</lpage><pub-id pub-id-type="pmid">27400948</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002F50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |